

Research article

Open Access

## Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors

Norio Matsushima\*<sup>1</sup>, Takanori Tanaka<sup>2</sup>, Purevjav Enkhbayar<sup>3</sup>,  
Tomoko Mikami<sup>1,4</sup>, Masae Taga<sup>1,4</sup>, Keiko Yamada<sup>1</sup> and Yoshio Kuroki<sup>5</sup>

Address: <sup>1</sup>School of Health Sciences, Sapporo Medical University, Hokkaido 060-8556, Japan, <sup>2</sup>RIKEN Genomic Sciences Center, Yokohama, Kanagawa 230-0045, Japan, <sup>3</sup>Faculty of Biology, National University of Mongolia, Ulaanbaatar-210646/377, Mongolia, <sup>4</sup>Department of Nursing, Sapporo City University, Sapporo, Hokkaido 060-0011, Japan and <sup>5</sup>Department of Biochemistry, School of Medicine, Sapporo Medical University, Hokkaido 060-8556, Japan

Email: Norio Matsushima\* - matusima@sapmed.ac.jp; Takanori Tanaka - gouhan@gsc.riken.jp;  
Purevjav Enkhbayar - enkhbayar@biology.num.edu.mn; Tomoko Mikami - t.mikami@scu.ac.jp; Masae Taga - m.taga@scu.ac.jp;  
Keiko Yamada - oyama@sapmed.ac.jp; Yoshio Kuroki - kuroki@sapmed.ac.jp

\* Corresponding author

Published: 21 May 2007

Received: 24 October 2006

BMC Genomics 2007, 8:124 doi:10.1186/1471-2164-8-124

Accepted: 21 May 2007

This article is available from: <http://www.biomedcentral.com/1471-2164/8/124>

© 2007 Matsushima et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Toll-like receptors (TLRs) play a central role in innate immunity. TLRs are membrane glycoproteins and contain leucine rich repeat (LRR) motif in the ectodomain. TLRs recognize and respond to molecules such as lipopolysaccharide, peptidoglycan, flagellin, and RNA from bacteria or viruses. The LRR domains in TLRs have been inferred to be responsible for molecular recognition. All LRRs include the highly conserved segment, LxxLxLxxNxL, in which "L" is Leu, Ile, Val, or Phe and "N" is Asn, Thr, Ser, or Cys and "x" is any amino acid. There are seven classes of LRRs including "typical" ("T") and "bacterial" ("S"). All known domain structures adopt an arc or horseshoe shape. Vertebrate TLRs form six major families. The repeat numbers of LRRs and their "phasing" in TLRs differ with isoforms and species; they are aligned differently in various databases. We identified and aligned LRRs in TLRs by a new method described here.


**Results:** The new method utilizes known LRR structures to recognize and align new LRR motifs in TLRs and incorporates multiple sequence alignments and secondary structure predictions. TLRs from thirty-four vertebrate were analyzed. The repeat numbers of the LRRs ranges from 16 to 28. The LRRs found in TLRs frequently consists of LxxLxLxxNxLxxLxxxxF/LxxLxx ("T") and sometimes short motifs including LxxLxLxxNxLxxLPx(x)LPxx ("S"). The *TLR7* family (TLR7, TLR8, and TLR9) contain 27 LRRs. The LRRs at the N-terminal part have a super-motif of *STT* with about 80 residues. The super-repeat is represented by *STTSTTSTT* or *\_TTSTTSTT*. The LRRs in TLRs form one or two horseshoe domains and are mostly flanked by two cysteine clusters including two or four cysteine residue.

**Conclusion:** Each of the six major TLR families is characterized by their constituent LRR motifs, their repeat numbers, and their patterns of cysteine clusters. The central parts of the *TLR1* and *TLR7* families and of *TLR4* have more irregular or longer LRR motifs. These central parts are inferred to play a key role in the structure and/or function of their TLRs. Furthermore, the super-repeat in the *TLR7* family suggests strongly that "bacterial" and "typical" LRRs evolved from a common precursor.

## Background

Toll-like receptors (TLRs) play a central role in innate immunity [1-3]. TLRs are type I integral membrane glycoproteins consisting of leucine rich repeat (LRR) motif in the ectodomain (ECD), and cytoplasmic signaling domains known as Toll IL-receptor (TIR) domains, joined by a single trans membrane helix (Figure 1). They recognize and respond to a variety of components derived from pathogenic or commensal microorganisms principally bacteria and viruses. These molecules include lipids such as lipopolysaccharide (LPS) from Gram-negative bacteria and peptidoglycan fragments from bacterial cell walls, proteins such as flagellin and nucleic acids such as single-stranded and double-stranded RNA and unmethylated CpG DNA from bacteria or viruses. The ECDs including LRRs have been inferred to recognize directly various ligands. The TLR family counts 10 members in human and 12 in mice and *Takifugu rubripes*. Six major families of vertebrate TLRs have been proposed in a molecular dendrogram [4].

Leucine-rich repeat (LRR)-containing domains are present in over 6000 proteins listed in PFAM, PRINTS, SMART, and InterPro data bases [5-8]. All LRR repeats can be divided into a highly conserved segment (HCS) and a variable segment (VS). The HCS part consists of an eleven residue stretch, LxxLxLxxNxL, or a twelve residue stretch, LxxLxLxxCxxL, in which "L" is Leu, Ile, Val, or Phe, "N" is Asn, Thr, Ser, or Cys, and "C" is Cys, Ser or Asn [7,9]. Seven classes of LRRs have been proposed, characterized by different lengths and consensus sequences of the VS part of repeats [9,10]. They are "RI-like", "CC", "bacterial", "SDS22-like", "plant specific", "typical", and "TpLRR". Each subfamily of small leucine-rich repeat proteoglycan (SLRP) has LRRs from more than one of the seven classes [8,11]. The structures of twenty-two different proteins that contain LRRs are available [12-51]. They include TLR3 and CD14 [48-50]. The LRR domains in all known structures adopt an arc shape. Most of the known LRR structures have a cap, which shields the hydrophobic core of the first LRR at the N-terminus or the last LRR at



**Figure 1**

Structural organization of vertebrate TLRs. Magenta is signal peptide sequence. Green is LRRNT (the cysteine clusters on the N-terminal side of LRRs) and LRRCT (the cysteine clusters on the C-terminal side of LRRs). Yellow is LRR domain. Blue is transmembrane region. Light blue is TIR domain.

the C-terminus. In extracellular proteins or extracellular domains, these caps frequently consist of cysteine clusters including two or four cysteine residues [8,9].

The indicated repeat number of LRRs and its "phasing" (that is, what segment or residue corresponds to the beginning of a repeating unit) in individual TLRs are different among the databases (or researchers) and species. This difference reflects the irregularity of LRR motifs in TLRs. Over one hundred complete TLRs are available. Several methods of protein secondary structure predictions such as Proteus and SSPro4.0 show a correspondence of about 75% [52-54]. For the identification of LRRs we propose a new method, which uses the known structures of several LRRs, multiple sequence alignments and secondary structure predictions of TLRs. This new method indicates that each of the six recognized TLR families can be characterized by its LRR motifs, their repeat number and the motifs of two cysteine clusters flanking the LRRs. The actual repeat number of LRRs is generally larger than those reported in the databases. The present analysis leads to the hypothesis that all the LRRs in TLRs form one or two horseshoe domains.

## Results

### A new method for the identification of LRRs within TLRs

#### LRR known structures

All of the LRR domains in one protein form a single continuous structure and adopt an arc or horseshoe shape. On the inner, concave face there is a stack of parallel  $\beta$ -strands and on the outer, convex face there are a variety of secondary structures such as  $\alpha$ -helix,  $3_{10}$ -helix, polyproline II helix, or a tandem arrangement of  $\beta$ -turns [8,55]. The HCS part of all the LRRs consists of LxxLxLxxNxL or LxxLxLxxCxxL, as noted, in which "L" is Leu, Ile, Val, or Phe, "N" is Asn, Thr, Ser, or Cys, and "C" is Cys, Ser or Asn [7,9]. The short  $\beta$ -strands are mostly formed by three residues at positions 3 through 5 in the HCS part. In most LRR proteins the  $\beta$ -strands on the concave face and (mostly) helical elements on the convex face are connected by short loops or  $\beta$ -turns. Four leucine residues at positions 1, 4, 6 and 11 participate in the hydrophobic core in LRR arcs. Similarly, conserved hydrophobic residues in the VS parts of the seven LRR classes participate in the hydrophobic core. The side chains of asparagine at position 9 form hydrogen bonds in the loop structure [6].

Structural alignments of the known LRR structures reveal that the LRR motif is surprisingly variable (Table 1). The lengths of LRRs range from 20 to 43 residues. Leucines at positions 1, 4, 6 and 11 of the HCS part are sometimes replaced by Met, Ala, or Cys, as seen in TLR3 [49,50], Internalin A (Inl-A) [26], and Internalin B (Inl-B) [22-24]. Leucines at positions 1 and 11 are also occupied by relatively hydrophilic residues such as Gly, Thr, Asn and Tyr.

Furthermore, asparagine at position 9 is occupied by hydrophobic residues such as Val, Leu and Ile. It is clear that many LRRs do not keep the complete HCS pattern and are irregular. Eighteen of the 22 known structures contain irregular LRRs. Most of the irregular HCSs can be classified into four groups; LxxLxLxx(L/I/M)xL, LxxLxLxx(R/K/E)xL, LxxLxLxx(N/S/T/A)xx, and LxxLxLxxxxx in which residues in boldface are irregular. Also there are rare examples, xVxxLxLxxNxL and PxxLxLxxNxL in follicle-stimulating hormone receptor (FSHr), and LxxLxGxxS/PxI in Inl-C and DLC1 (Table 1). Furthermore, an irregular LRR with (L/x)xx(L/A)xCxx(L/R)xLxxVPxxIPxx, which belongs to the "bacterial" motif, is frequently observed at the first LRR (LRR1) at the N-terminus of the LRR domain (Table 1).

#### Multiple sequence alignment

Mammalian TLR2 contains 20 LRRs, as described later. The PFAM program detects only 5–7 of the 20 LRRs, while the InterPro database (20 August, 2006) counts 13 in chicken, 14 in human, Cynomolgus monkey, dog and Chinese hamster, and 18 in bovine (Table 2). Figures 2 and 3 show the multiple sequence alignment of the LRR domain in mammalian TLR2 from 14 species. The sixth LRR (LRR6) shows canonical and irregular LRRs whose HCS parts consist of LxxLxLxx(S/T/N)xL and LxxLxLxx(Q/D)xL or LxxLxLxxLxL, respectively. The VS part is "typical". Both canonical and irregular LRR are also seen in LRR9 and LRR10. Furthermore, the HCS part of LRR4 shows LxxLxLxxNxY in which position 11 is tyrosine. This pattern was recognized in the known structures of TLR3 and lingo-1 (Table 1). The pairwise sequence identities are >35%. Thus, all LRRs in TLR2s from the 14 species can be reasonably regarded as an LRR motif.

#### Protein secondary structure prediction

The result of the protein secondary structure prediction of human TLR2 having 20 LRRs is shown in Figure 4. Both SSpro4.0 and Proteus predict that 15 of the 20 LRRs prefer  $\beta$ -strands at positions 3 through 5 and/or its neighboring positions in the HCS part. They include all five irregular motifs, LRR4, LRR5, LRR7, LRR9, and LRR11. The occurrence of  $\beta$ -strands in LRR6 is predicted only by Proteus. However, LRR6 with the HCS part of LEELEIDA $\underline{S}$ DL is clearly a canonical LRR. All twenty including LRR6 can be reasonably identified as LRR motifs.

#### The identification of LRRs within TLRs

These analyses of the known LRR structures, the multiple sequence alignments and the secondary structure predictions of TLR2 provide strong evidence that allow us to identify LRRs over an extended range of sequences and inferred structures. Taken together four steps for the identification of LRRs in each member of TLRs were used.

*Step 1.* Detection of LRRs by the PFAM program

*Step 2.* Identification of a candidate LRR that can not be recognized by PFAM.

*Step 3:* Evaluation of protein secondary structure predictions by Proteus and SSpro4.0.

*Step 4.* Determination of all LRRs in each member based on the results obtained by *Steps 1–3*.

In *Step 2*, the LRR candidates are selected using the criterion that they are longer than 18 residues and that the HCS part consisting of LxxLxLxxNxL occupies at least hydrophobic residues at positions 4 and 6. The candidate includes irregular motifs that are similar to LRRs recognized by the known structures. In case there are TLRs from many species, multiple sequence alignments are also considered for identification. In *Step 3*, the preference of  $\beta$ -strand in the HCS part of the LRR candidate selected by *Step 1* and *Step 2* was investigated. In *Step 4*, when the candidate prefers  $\beta$ -strand by either Proteus or SSpro4.0 (at least in one species), it is identified as an LRR. In some cases such as LRR12 in TLR14, the initial LRR candidate was changed into another LRR based on the results of the secondary structure prediction. The crystal structure of human TLR3 [52,53] contains 25 LRRs. The present method confirmed this. In contrast, the PFAM and SMART programs predicted only 16–17 LRRs and the databases have reported 22 LRRs (Table 2).

There are two exceptions. In five mammalian TLR6s with 20 LRRs, LRR9, PTLN(E/V/L)TL(N/Q)H(I/V), that contains Pro at position 1 is not predicted to have a  $\beta$ -strand by both prediction methods (Figure 4). However, this pattern is seen in FSHr (Table 1). Similarly, in human and pig TLR10 with 20 LRRs LRR10, G $\underline{G}$ K(A/V)YLDHNS $\underline{E}$ , is not predicted to have a  $\beta$ -strand by both programs (Figure 4). However, this pattern shows remarkable similarity with the sixteenth LRR (LRR16) in TLR7 and TLR8 with 27 LRRs.

#### LRRs within TLRs

##### LRR motifs

The repeat number and "phasing" of LRRs in TLRs are summarized in Table 2 and Figures 5, 6, 7, 8, 9, and 10. The number of LRRs identified within TLRs range from 16 to 28; these numbers are larger than those reported in most databases. The "typical"; "T", LRR, LxxLxLxxNxLxx-LxxxxFxxLxx, occurs most frequently followed by shorter motifs including LxxLxLxxNxLxxLPx(x)LPxx ("bacterial"; "S") with 19–21 residues. Moreover, all of the C-terminal LRR consists of LxxLxLxxNP(F/L)xCxCxxxx(F/L)xxxx. The TLRs contain a variety of irregular LRRs (Figures 5, 6, 7, 8, 9, and 10). The first LRR at the N-terminus (LRR1) is fre-

**Table 1: Irregular LRR motifs observed in the known structures of LRR-containing proteins**

Protein <sup>a</sup>	N <sup>b</sup>	Position	Amino acid sequence <sup>c</sup> <b>LxxLxLxxNxL</b>	Irregular LRRs	PDB
TLR3	25	LRR1	<b>HEVADC</b> SHLKL	TQVPDDLPTN	1ZIW /2A0Z
		LRR9	LFGLFLNN <b>V</b> QL	GPSLTEKLCLELANTS	
		LRR13	VRYLNLKRS <b>F</b> T	KQSISLASLPKIDDFSQWLKC	
		LRR15	LKYLSLSNS <b>F</b> T	SLRTLNETFVSLAHSP	
		LRR18	IFEIYLSYN <b>K</b> Y	LQLTRNSFALVPS	
		LRR19	LQRLMLRR <b>V</b> AL	KNVDSSSPFQPLRN	
CD14	11	LRR1	<b>AADVELYGGGR</b>	SLEYLLKRVDT <b>EADL</b> GQFTDIKSL	1WWL
		LRR2	LKRLTVRA <b>A</b> RI	PSRILFGALRVLGISG	
		LRR3	LQELTLEN <b>L</b> EV	TGTAPPPLEATGPD	
		LRR4	LNILNLRN <b>V</b> SW	ATRAWLAE <b>LQ</b> QWLKPG	
		LRR5	LKVLSIA <b>QA</b> HS	LNFSCEQVRV <b>F</b> PA	
		LRR7	LQVLALRN <b>AG</b> M	ETPSGVC <b>S</b> ALAAAR <b>V</b> Q	
Slit	6	LRR1	<b>G</b> TTVDCT <b>GR</b> GL	KEIPRDIPLH	1W8A
Lingo-1	14	LRR8	LIVLRRLRHL <b>N</b> I	NAIRDYSFKRL <b>Y</b> R	2ID5
		LRR9	LKVLEISH <b>WP</b> Y	LDTMTPNCL <b>Y</b> GLN	
Decorin	12	LRR1	LRVVQCS <b>D</b> LGL	EKVPKDL <b>P</b> PD	1XCD
Biglycan	12	LRR1	LRVVQCS <b>D</b> LGL	KAVPKEI <b>S</b> PD	2FT3
FSHr	10	LRR6	LQKVL <b>LDI</b> Q <b>D</b> N	INIHTIERN <b>S</b> FVGL <b>S</b> FE	1XWD
		LRR7	<b>S</b> VILWLN <b>K</b> NGI	QEIHN <b>C</b> AFNG <b>T</b> Q	
		LRR9	<b>P</b> VILDIS <b>R</b> TRI	HSLPS <b>Y</b> GL <b>E</b> N	
Inl-A	16	LRR1	VTT <b>LQ</b> AD <b>R</b> LGI	KSIDGLE <b>Y</b> L <b>N</b> N	1O6V
Inl-C	7	LRR1	VQ <b>N</b> F <b>NG</b> DNS <b>N</b> I	QSLAG <b>M</b> Q <b>F</b> FT <b>N</b>	1XEU
		LRR7	V <b>N</b> WID <b>L</b> T <b>G</b> Q <b>K</b> C	VNEPV <b>K</b> Y <b>Q</b> PE <b>L</b>	
U2snRNPA'	5	LRR1	DRE <b>L</b> DLRG <b>Y</b> KI	PVIR <b>N</b> L <b>G</b> AT <b>L</b> D <b>Q</b>	1A9N
RabGGT $\alpha$	5	LRR1	VRV <b>L</b> H <b>L</b> A <b>H</b> K <b>D</b> L	TVL <b>C</b> H <b>L</b> E <b>Q</b> L <b>L</b> L	1DCE
DLC1	6	LRR1	<b>K</b> VEL <b>H</b> <b>G</b> M <b>I</b> P <b>P</b> I	E <b>K</b> M <b>D</b> A <b>T</b> L <b>S</b> T <b>L</b> K <b>A</b>	1DS9
TAP	4	LRR1	<b>Q</b> QAL <b>D</b> L <b>K</b> GL <b>R</b> S	DPDLVAQ <b>N</b> ID <b>V</b> LN <b>R</b> R <b>S</b> C <b>M</b> A <b>A</b> T <b>L</b> R <b>I</b> I	1FT8
				E <b>E</b> N <b>I</b> P <b>E</b>	
PGIP	10	LRR1	V <b>N</b> N <b>L</b> D <b>S</b> GL <b>N</b> L	PKPY <b>P</b> IP <b>S</b> LAN <b>L</b> PY <b>L</b>	1OGQ
YoPM	16	LRR1	A <b>H</b> E <b>L</b> E <b>L</b> NN <b>L</b> GL	S <b>S</b> L <b>P</b> E <b>L</b> PP <b>H</b>	1G9U
		LRR16	V <b>E</b> D <b>L</b> R <b>M</b> NS <b>E</b> R <b>V</b>	DPY <b>E</b> FA <b>H</b> ET <b>T</b> D <b>K</b> LE <b>D</b> D <b>V</b> FE	
hRI	16	LRR15	LE <b>Q</b> L <b>V</b> LY <b>D</b> I <b>Y</b> W	S <b>E</b> EM <b>E</b> D <b>R</b> L <b>Q</b> A <b>L</b> E <b>K</b> DK <b>P</b>	1Z7X
pRI	17	LRR1	W_ <b>N</b> L <b>D</b> I <b>H</b> CE <b>Q</b> L	S <b>D</b> A <b>R</b> W <b>T</b> E <b>L</b> PL <b>Q</b> Q	2BNH
RanGAP	10	LRR2	LE <b>I</b> A <b>E</b> F <b>S</b> D <b>I</b> F <b>T</b>	GR <b>V</b> K <b>D</b> E <b>I</b> P <b>E</b> A <b>L</b> R <b>L</b> L <b>L</b> Q <b>A</b> L <b>L</b> K <b>C</b> P <b>K</b>	1YRG
cTmod	5	LRR1	LEE <b>V</b> N <b>L</b> NN <b>I</b> M <b>N</b>	IP <b>V</b> PT <b>L</b> K <b>A</b> C <b>A</b> E <b>A</b> L <b>K</b> T <b>N</b> T <b>Y</b>	1IO0
		LRR2	V <b>K</b> K <b>F</b> S <b>I</b> V <b>G</b> T <b>R</b> S	N <b>D</b> P <b>V</b> A <b>F</b> A <b>L</b> A <b>E</b> M <b>L</b> K <b>V</b> N <b>N</b> T	
		LRR4	L <b>I</b> E <b>L</b> R <b>I</b> D <b>N</b> Q <b>S</b> Q	P <b>L</b> G <b>N</b> N <b>V</b> E <b>M</b> E <b>I</b> A <b>N</b> M <b>L</b> E <b>K</b> N <b>T</b> T	
		LRR5	LL <b>K</b> F <b>G</b> Y <b>H</b> F <b>T</b> Q <b>Q</b>	P <b>R</b> L <b>R</b> A <b>S</b> N <b>A</b> M <b>M</b> N <b>N</b> D <b>L</b> V <b>R</b> K	
		LRR5	LL <b>R</b> V <b>G</b> I <b>S</b> F <b>A</b> S <b>M</b>	E <b>A</b> R <b>H</b> R <b>V</b> S <b>E</b> A <b>L</b> E <b>R</b> N <b>Y</b> E <b>R</b> V <b>L</b>	
ceTmod	5	LRR1	L <b>K</b> E <b>V</b> N <b>I</b> N <b>N</b> M <b>K</b> R	V <b>S</b> K <b>E</b> R <b>I</b> R <b>S</b> L <b>I</b> E <b>A</b> A <b>C</b> N <b>S</b> K <b>H</b>	1PGV
		LRR4	I <b>V</b> E <b>F</b> K <b>A</b> D <b>N</b> Q <b>R</b> Q	S <b>V</b> L <b>G</b> N <b>Q</b> V <b>E</b> M <b>D</b> M <b>M</b> A <b>I</b> E <b>E</b> N <b>E</b> S	
		LRR5	LL <b>R</b> V <b>G</b> I <b>S</b> F <b>A</b> S <b>M</b>	E <b>A</b> R <b>H</b> R <b>V</b> S <b>E</b> A <b>L</b> E <b>R</b> N <b>Y</b> E <b>R</b> V <b>L</b>	
Skp2	11	LRR1	W <b>Q</b> T <b>L</b> D <b>L</b> T <b>G</b> K <b>N</b> L	H <b>P</b> D <b>V</b> T <b>G</b> R <b>L</b> L <b>S</b> Q <b>G</b>	1FQV /2ASS
		LRR4	L <b>Q</b> N <b>L</b> S <b>L</b> W <b>F</b> L <b>R</b> L	S <b>D</b> P <b>I</b> V <b>N</b> T <b>L</b> A <b>K</b> N <b>S</b> N	
		LRR7	I <b>T</b> Q <b>L</b> N <b>L</b> S <b>G</b> Y <b>R</b> K	N <b>L</b> Q <b>K</b> S <b>D</b> L <b>S</b> T <b>L</b> V <b>R</b> R <b>C</b> P <b>N</b>	
		LRR10	L <b>K</b> T <b>L</b> Q <b>V</b> F <b>G</b> I <b>V</b> P	D <b>G</b> T <b>L</b> Q <b>L</b> L <b>K</b> E <b>A</b>	

<sup>a</sup>FSHr, follicle-stimulating hormone receptor; Inl-A, internalin A; Inl -C, internalin C; U2snRNPA', spliceosomal U2A' protein; RabGGT $\alpha$ , rab geranylgeranyltransferase  $\alpha$ -subunit; DLC-1, *Chlamydomonas* outer arm dynein light chain 1; TAP, mRNA export factor; PGIP, polygalacturonase-inhibiting protein; RI, ribonuclease inhibitor, RanGAP, GTPase-activating protein; Tmod, tropomodulin; Skp2, S-phase kinase-associated protein 2; h, human, p, pig; ce, *Caenorhabditis elegans*. <sup>b</sup>N; the repeat number of LRRs identified in individual known LRR structures. <sup>c</sup>HCS, highly conserved segment of LRR; VS, variable segment of LRR. Residues in boldface cause irregular motif.

**Table 2: The repeat number of LRRs and its flanking cysteine clusters in vertebrate TLRs**

Famliy <sup>a</sup>	Protein	Species <sup>b</sup>	N <sub>L</sub> <sup>c</sup>	LRRNT <sup>d</sup>	LRRCT <sup>d</sup>	N <sub>B</sub> <sup>e</sup>
TLR1	TLR1	h, m, p	20(8-9)	No	Cx <sub>25</sub> Cx <sub>20</sub> C	1
	"	t	21	Cx <sub>29</sub> Cx <sub>20</sub> C	Cx <sub>29</sub> Cx <sub>20</sub> C	1
	TLR2	h, m, p, b, r, d, ra, g, ho, dwb, ha, cm, n	20(14-18)	Cx <sub>5</sub> C	Cx <sub>24</sub> Cx <sub>20</sub> C	1
	TLR2.1	c	20(13)	Cx <sub>2</sub> Cx <sub>5</sub> CxC	Cx <sub>24</sub> Cx <sub>20</sub> C	1
	TLR2.2	c	20(13)	Cx <sub>2</sub> Cx <sub>5</sub> CxC	Cx <sub>24</sub> Cx <sub>20</sub> C	1
	TLR2	t	20	Cx <sub>2</sub> Cx <sub>5</sub> CxC	Cx <sub>25</sub> Cx <sub>20</sub> C	1
	TLR2	jf	19	Cx <sub>2</sub> Cx <sub>5</sub> CxC	Cx <sub>25</sub> Cx <sub>20</sub> C	1
	TLR2	z	21	Cx <sub>3</sub> Cx <sub>5</sub> CxC	Cx <sub>24</sub> Cx <sub>20</sub> C	1
	TLR6	h, m, r, p, b	20(13-14)	No	Cx <sub>25</sub> Cx <sub>20</sub> C	1
	TLR10	h, p	20(12)	No	Cx <sub>25</sub> Cx <sub>20</sub> C	1
TLR14	t, z	21	Cx <sub>10</sub> C	Cx <sub>25</sub> Cx <sub>20</sub> C	1	
TLR3	TLR3	h, m, b, r, bu, rm, z	25(22-24)	Cx <sub>8</sub> C	Cx <sub>25</sub> Cx <sub>18</sub> C	1
	"	t	25	Cx <sub>8</sub> C	Cx <sub>26</sub> Cx <sub>18</sub> C	1
	"	jf	27	Cx <sub>8</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	1
	TLR	as	27	Cx <sub>15</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	1
	"	rt	27	Cx <sub>15</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	1
	"	go	27	Cx <sub>14</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	1
	TLRII	rt	27	Cx <sub>6</sub> Cx <sub>17</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	1
TLR4	TLR4	h, lg, pc, ob, or	23(21)	Cx <sub>10</sub> C	Cx <sub>23</sub> Cx <sub>17</sub> C	1
	"	m, p, r, ch, ho, b, ab, n,	23(18-19)	Cx <sub>10</sub> C	Cx <sub>23</sub> Cx <sub>18</sub> C	1
	"	ha, ra	23	Cx <sub>10</sub> C	Cx <sub>23</sub> Cx <sub>15</sub> C	1
	TLR4b	z	23	Cx <sub>10</sub> C	Cx <sub>23</sub> Cx <sub>18</sub> C	1
	TLR4	h [Q5VZ17]	16	Cx <sub>10</sub> C	Cx <sub>23</sub> Cx <sub>18</sub> C	1
"	d	16	No	Cx <sub>23</sub> C	1	
TLR5	TLR5	h, m, r, p, b, jhm	22(15-16)	Cx <sub>11</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	1
	"	t	22	Cx <sub>10</sub> C	Cx <sub>24</sub> Cx <sub>22</sub> C	1
	"	rt	22	Cx <sub>8</sub> C	Cx <sub>27</sub> C	1
	TLRS5	t	23	Cx <sub>8</sub> C	Cx <sub>26</sub> C	1
TLR11	TLR11	M	25(11)	Cx <sub>17</sub> Cx <sub>11</sub> Cx <sub>20</sub> C	Cx <sub>24</sub> Cx <sub>19</sub> C	1
	TLR12	m	24(17)	Cx <sub>17</sub> Cx <sub>11</sub> Cx <sub>20</sub> C	Cx <sub>24</sub> Cx <sub>19</sub> C	1
	TLR13	m	27(21)	Cx <sub>11</sub> C	Cx <sub>24</sub> Cx <sub>16</sub> C	1
	TLR21	t	27	Cx <sub>10</sub> C	Cx <sub>24</sub> Cx <sub>15</sub> C	1
	TLR22	t	27	Cx <sub>8</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	1
	TLR23	t	27	Cx <sub>14</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	1
TLR7	TLR7	H, m, d	27(27-28)	Cx <sub>14</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	2
	"	t	27	Cx <sub>12</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	2
	TLR8	h, m, p	27(24-26)	Cx <sub>12</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	2
	"	t	27	Cx <sub>13</sub> C	Cx <sub>24</sub> Cx <sub>18</sub> C	2
	TLR9	h, m, p, b, d, ca, ho, s, mnm	27(26)	Cx <sub>9</sub> C	Cx <sub>23</sub> Cx <sub>18</sub> C	2
	"	t, jf, gsb	27	Cx <sub>10</sub> C	Cx <sub>23</sub> Cx <sub>18</sub> C	2
TLR	gp	28, 26	?	Cx <sub>24</sub> Cx <sub>18</sub> C	2	
Others	TLRa	jl	21	Cx <sub>8</sub> C	Cx <sub>22</sub> C <sub>12</sub> C	1
	TLRb	jl	21	Cx <sub>8</sub> C	Cx <sub>22</sub> Cx <sub>20</sub> C	1
	TLR15	c	21	No	Cx <sub>24</sub> Cx <sub>20</sub> C	2

<sup>a</sup>The six families and others. <sup>b</sup>Abbreviations: ab, American bison; as, Atlantic salmon; b, bovine; c, chicken; ca, cat; ch, Chinese hamster; cm, Cynomolgus monkey; d, dog; dwb, Domestic water buffalo; g, goat; go, Goldfish; gp, green puffer; gsb, Gilthead sea bream; h, human; ha, hamster; ho, horse; jf, Japanese flounder; jhm, Japanese house mouse; jl, Japanese lamprey; lg, lowland gorilla; m, mouse; mnm, Ma's night monkey; n, Nilgai; ob, Olive baboon; or, Orangutan; p, pig; pc, Pygmy chimpanzee; r, rat; ra, rabbit; rm, Rhesus macaque; rt, Rainbow trout; s, sheep; t, Takifugu rubripes; z, Zebrafish. <sup>c</sup>N<sub>L</sub>: the repeat number of LRRs. The number of parenthesis is N<sub>L</sub> reported in the Interpro database. <sup>d</sup>LRRNT, the cysteine clusters on the N-terminal side of LRRs; LRRCT, the cysteine clusters on the C-terminal side of LRRs. <sup>e</sup>N<sub>B</sub>: the number of horseshoe domains of the LRRs.

	LRR1	LRR2	LRR3	LRR4		
	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL		
bTLR2	-----MPRALWTAWVAVI ILS-TEGASDQASSLSCDPTGVC DGHRSRLNS IPSGLTAGVKSLDL SNNDIYVGNRDLQRCVNLKTLRLGANEIHTVEEDSFFHLRNLEYLDL SYNRLSNLSSWFRLSYLKFNLNLGNLYKTL					
nTLR2	-----MPRALWPAAVVA I ILS-MEGASDKASSLSCDPTGVC DGRSRLNS IPSGLTAGVKSLDL SNNDIYVGNRDLQRCVNLKTLRLGANEIHTVEEDSFFHLRNLEYLDL SYNRLSNLSSWFRLSYLKFNLNLGNLYKTL					
dwbTLR2	-----MPRALWTAWVAVI ILS-MEGASHQASSLSCDPTGVC DGHRSRLNS IPSGLTDGVKSLDL SNNDIYVSNRDLQRCVNLKTLRLGANEIHTVEEDSFFHLRNLEYLDL SYNRLSNLSSWFRLSYLKFNLNLGNVYKTL					
gTLR2	-----MPRALWTAWVAVI ILS-MEGASHQASSLSCDPTGVC DGHRSRLNS IPSGLTDGVKSLDL SNNDIYVSNRDLQRCVNLKTLRLGANEIHTVEEDSFFHLRNLEYLDL SYNRLSNLSSWFRLSYLKFNLNLGNVYKTL					
pTLR2	-----MPCALWTAAVLG I V ILSLKEGAPHQASSLSCDPAGVCDGRSRLSS IPSGLTAAVKSLDL SNNRIAYVGSDDLRCVNLRALRAGANSIHTVEEDSFFSLGSLEHLDSL SYNHLSNLSSWFRLSYLKFNLNLGNPYKTL					
hoTLR2	-----MPHALWTWVVLGAVI ILSLKEGVPDQPSLSCDPTGVC DGRSRLNS IPSGLTAAVKSLDL SNNKIASVGNSDLKWCVNLKALRLGSDINTI EEDSFSSLRSLEHLDSL SNNHLSNLSSWFRLSYLKFNLNLGTYKTL					
hTLR2	-----MPHTLWMVWVLGVI ILSLKEESSNQ-ASLSCDRNG I CKGSSGSLNS IPSGLTEAVKSLDL SNNRITY ISNSDLQRCVNLQALVLT SNGINTI EEDSFSSLRSLEHLDSL SNNHLSNLSSWFRLSYLKFNLNLGNPYKTL					
cmTLR2	-----MPHTLWMVWVLGVI ILSLKEESSNQ-ASLSCDHNG I CKGSSGSLNS IPSGLTEAVKSLDL SNNRITY ISNSDLQRCVNLQALVLT SNGINTI EEDSFSSLRSLEHLDSL SNNHLSNLSSWFRLSYLKFNLNLGNPYKTL					
dTLR2	-----MSRVLWTLWVVLGAVTNSLKEEAPDQSSLSCDPTGVC DGRSRLNSMPSGLTAAVRSDL SNNIITY IGNSDLRDCVNLKALRLSNGINTI EEEESFSLWSLEHLDSL SNNHLSNLSSWFRLSYLKFNLNLGNPYKSL					
raTLR2	-----MPPALWTWVWALGAVI SLPTEG-APDLP S LSCDPAG I CDGRSRSFQS IPSGLTAAVKSLDL SNNIITY IRDSDLHRCVHLRALMLMSNGIDT I DEDSFSSLRSLEHLDSL SNNHLSHLSA WFRP LSYLKFNLNLGNPYRTL					
mTLR2	-----MLRALWLFWVILVAITVLFKSR-CSAQESLSCDASGVC DGRSRLS IPSGLTAAVKSLDL SNNKITY IGHGDLRACANQVLLKSSRINTI EGDFAFYSLSLEHLDSL SNNHLSSWFRLSYLKFNLNLGMNPYRTL					
rTLR2	-----MLQALWLFWVILMAV ILSLREG-HSAQASLSCDAAGVCDGSSRSFQS IPSGLTAAVKSLDL SNNKITY IGHGDLRACVNLRLVLT SSGINTI EGDFAFYSLSLEHLDSL SNNHLSSWFRLSYLKFNLNLGMNPYRTL					
chTLR2	-----MLHVLWTFWVILVAMDTL SRRG-CSAQASLSCDAAGVCDGSSRSFQS IPSGLTAAVKSLDL SNNKITY IGHGDLRACVNLRLVLT SSGINTI EEDAFSSLKLEHLDSL SNNHLSSWFRLSYLKFNLNLGNPYRTL					
cTLR2.1	MFNQSKQKPTMKLMQAWL IY TALAHLPEEQALRQACLSCDATQSCNCSFMGLDF I PPGLTGKI TVLNLAHNR I KLR I THDLQKAVNLR TLLQSNQ I S I DEDSFSGQGLLEHLDSL SNNLAHLS PWFGLPFLSLQHLRI QGNSYSDL					
cTLR2.2	-----MHTWKMWAICTALAAHLPEEQALRQACLSCDATQSCNCSFMGLDF I PPGLTGKI TVLNLAHNR I KLR I THDLQKAVNLR TLLQSNQ I S I DEDSFSGQGLLEHLDSL SNNLAHLS PWFGLPFLSLQHLRI QGNSYSDL					
	LRR5	LRR6	LRR7	LRR8	LRR9	LRR10
	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL
bTLR2	GETSLFSLH.PNLRLTKVGNNSFTEIHEKDFTGLTFLEELEISAQNLQ IYVPSKLSIQNISHL IHLKQP VLLVDI IVDI VSSLDCELEL.RDTNLHTFHSEAS I SEMSTSVKLL IFRNVQFTDES FVEVVKLFNYVSG I LEVEFDCTH					
nTLR2	GETSLFSLH.PDLRLTKVGNNSFTEIHEKDFTGLTFLEELEISAQNLQ IYVPSKLSIQNISHL IHLKQP VLLVDI IVDI VSSLDCELEL.RDTNLHTFHSEAS I SEMSTSVKLL IFRNVQFTDES FVEVVKLFNYVSG I LEVEFDCTH					
dwbTLR2	GETSLFSLH.PNLRLTKVGNNSFTEIHEKDFTGLTFLEELEISAQNLQ IYVPSKLSIQNISHL IHLKQP VLLVDI IVDI VSSLDCELEL.RDTNLHTFHSEAS I SEMSTSVKLL IFRNVQFTDES FVEVVKLFNYVSG I LEVEFDCTH					
gTLR2	GETSLFSLH.PNLRLTKVGNNSFTEIHEKDFTGLTFLEELEISAQNLQ IYVPSKLSIQNISHL IHLKQP VLLVDI IVDI VSSLDCELEL.RDTNLHTFHSEAS I SEMSTSVKLL IFRNVQFTDES FVEVVKLFNYVSG I LEVEFDCTH					
pTLR2	GETPLFSLH.PNLRLTKVGNNSFTEIHEKDFTGLTFLEELEISAQNLQ IYVPSKLSIQNISHL IHLKQP VLLVDI IVDI VSSLDCELEL.RDTNLHTFHSEAS I SEMSTSVKLL IFRNVQFTDES FVEVVKLFNYVSG I LEVEFDCTH					
hoTLR2	GETSLFSLH.TNLRILKVGNI- IHFTEIQGDFAGLTFLEELEIDATNLQRYEPKFSKSIQNISHL IHLRMRPALLPK I FVDLLSSLKYLKLRNTDFSTFNFDVSI NEPSTVMKFFPRKAEITDASFTE I V KLLNYISGVSEAEFDCTL					
hTLR2	GETSLFSLH.TKLQILRVGNMDFTK IQRKDFAGLTFLEELEIDASDLQSYEPKFSKSIQNISHL IHLKQVILL I FVDVTSVVECELEL.RDTDLDTFHSELSI TGETNSL I KKFTRFNK I TDESFLQVMKLLNQ I SGLLELEFDCTL					
cmTLR2	GETSLFSLH.TKLRILRVGNMDFTK IQRKDFAGLTFLEELEIDASDLQSYEPKFSKSIQNISHL IHLKQVILL I FVDVTSVVECELEL.RDTDLDTFHSELSI TGETNSL I KKFTRFNK I TDESFLQVMKLLSQ I SGLLELEFDCTL					
dTLR2	GETPLFSQL.TNLRILKVGNIYSFTEIQDKDFAGLTFLEELEIDASDLQRYEPKFSKSIQNISHL IHLRMRPALLPK I FVDLLSSLKYLKLRNTDFSTFNFDVSI NEPSTVMKFFPRKAEITDASFTE I V KLLNYISGVSEAEFDCTL					
raTLR2	GETSLFSLH.PHLRLTKVGSYAFANIRRMDFAGVRSLELEIDGNSLQSYEPKFSKSIQNISHL IHLRMRPALLPK I FVDLLSSLKYLKLRNTDFSTFNFDVSI NEPSTVMKFFPRKAEITDASFTE I V KLLNYISGVSEAEFDCTL					
mTLR2	GVTSLFPNL.TNLRILKVGNIYSFTEIQDKDFAGLTFLEELEIDASDLQRYEPKFSKSIQNISHL IHLRMRPALLPK I FVDLLSSLKYLKLRNTDFSTFNFDVSI NEPSTVMKFFPRKAEITDASFTE I V KLLNYISGVSEAEFDCTL					
rTLR2	GETSLFSLH.TNLRILKVGNIYSFTEIQDKDFAGLTFLEELEIDASDLQRYEPKFSKSIQNISHL IHLRMRPALLPK I FVDLLSSLKYLKLRNTDFSTFNFDVSI NEPSTVMKFFPRKAEITDASFTE I V KLLNYISGVSEAEFDCTL					
chTLR2	GETPLFLN.THLQILRVGNVATFSG IRRDFAGLTFLEELEIDASDLQRYEPKFSKSIQNISHL IHLRMRPALLPK I FVDLLSSLKYLKLRNTDFSTFNFDVSI NEPSTVMKFFPRKAEITDASFTE I V KLLNYISGVSEAEFDCTL					
cTLR2.1	GESSPSSL.RNLSHLGN-PQFS I I RQGNFEG I VFLNLRIDGDNLSQYEPKFSKSIQNISHL IHLRMRPALLPK I FVDLLSSLKYLKLRNTDFSTFNFDVSI NEPSTVMKFFPRKAEITDASFTE I V KLLNYISGVSEAEFDCTL					
cTLR2.2	GESSPSSL.RNLSHLGN-PQFS I I RQGNFEG I VFLNLRIDGDNLSQYEPKFSKSIQNISHL IHLRMRPALLPK I FVDLLSSLKYLKLRNTDFSTFNFDVSI NEPSTVMKFFPRKAEITDASFTE I V KLLNYISGVSEAEFDCTL					

**Figure 2**

The multiple sequence alignment of LRRs within mammalian TLR2 from 14 species. bTLR2 [Q95LA9], nTLR2 [Q2V897], dwbTLR2 [Q2PZH4], gTLR2 [ABI31733], pTLR2 [Q59H18], hoTLR2 [AAR08196], hTLR2 [O60603], cmTLR [Q95M53], dTLR2 [Q689D1], raTLR2 [AAM50059], mTLR2 [Q9QUN7], rTLR2 [Q6YGU2], chTLR2 [Q9R1F8], cTLR2.1 [Q9DD78], cTLR2.2 [Q9DGB6]. Abbreviations: b, Bovine; n, nilgai; dwb, domestic water buffalo; g, goat; p, pig; ho, horse; h, human; cm, Cynomolgus monkey; d, dog; ra, rabbit; m, mouse; r, rat; ch, Chinese hamster; c, chicken. This panel shows the sequences from the N-termini to LRR10.

quently irregular, e.g. (L/x)xx(L/A)xCxx(L/R)xLxxVPxx-IPxx. This motif has been seen in the structures of TLR3, Slit, decorin, and biglycan, as noted. (Table 1). Methionine and tryptophan sometimes occupy positions 1, 4, 6 and 11 in the LxxLxLxxNxL motif, which are strongly hydrophobic. Moreover, as recognized in the known LRR structures, there are rare examples, xVxxLxLxxNxL, PxxLxLxxNxL and LxxLxGxxS/PxI. The first motif is sometimes observed in LRR7 in human TLR10, LRR8 in Takifugu rubripes TLR14, LRR4 in chicken TLR15, LRR8 in human TLR4, and LRR16 in human TLR9 (Figure 5, 6, 7, 8, 9, and 10). Furthermore, the HCS parts of a twelve residue stretch, LxxLx(L/V/M/F)xx(S/N)xx(F/M), are sometimes observed; they include LRR5 in TLR2 from pig, bovine, nilgai, and domestic water buffalo with 20 LRRs (Figures

2 and 3), LRR11 in mouse TLR4 with 23 LRRs, and LRR14 in TLR4 from pig, bovine, rabbit, and nilgai with 23 LRRs.

*LRRs in the six major families of TLRs*

There are six major families of vertebrate TLRs [4]. The TLR1 family consists of TLR1, TLR2, TLR6 and TLR10. This family contains 19–21 LRRs and has fewer numbers than do the other families except for Dog TLR4 [Q8SQH3] [56] and human TLR4 variant [Q5VZ17] in the TLR4 family. Mammalian TLR1 contains 20 LRRs (Table 2). In contrast, Takifugu rubripes TLR1 [4] has one additional LRR at the N-terminus whose sequence is RNYIDLSS-RNLSSVPGDLPKE, that is a "bacterial" type. Mammalian and Takifugu rubripes TLR2 contains 20 LRRs. Japanese flounder TLR2 lacks one LRR that corresponds to LRR7 in

	LRR11 LxxLxLxxNxL	LRR12 LxxLxLxxNxL	LRR13 LxxLxLxxNxL	LRR14 LxxLxLxxNxL	LRR15 LxxLxLxxNxL	Lx
bTLR2	DGIGDFRALSLDRIRHLGNVETLTIIRKLIHPQFFLFDLSSIYPLTGKVRVVTIENSKVFLVPCLLSQHLKSEYLDLSENLMSEETLKNACKDAWPFQLTVLRQNRKLSLEKTGELLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
nTLR2	DGIGDFRALSLDRIRHLGNVETLTIIRKLIHPQFFLFDLSSIYPLTGKVRVVTIENSKVFLVPCLLSQHLKSEYLDLSENLMSEETLKNACKDAWPFQLTVLRQNRKLSLEKTGELLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
dwbTLR2	DGIGDFRALSLDRIRHLGNVETLTIIRKLIHPQFFLFDLSSIYPLTGKVRVVTIENSKVFLVPCLLSQHLKSEYLDLSENLMSEETLKNACKDAWPFQLTVLRQNRKLSLEKTGELLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
gTLR2	DGIGDFRALSLDRIRHLGNVETLTIIRKLIHPQFFLFDLSSIYPLTGKVRVVTIENSKVFLVPCLLSQHLKSEYLDLSENLMSEETLKNACKDAWPFQLTVLRQNRKLSLEKTGELLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
pTLR2	NGRDFPSTALDTIKSLGNVETLTVRRHLHIPQFFLFDLRSIYSLTGAVKRTIENSKVFLVPCLLSQHLKSEYLDLSENLMSEETLKNACEHAWPFQLTVLRQNRKLSLEKTGEVLTLLKLNLLDLSKNNFLSMPETCQWPGKMK					
hoTLR2	DGLGEFRTPDIDKIKVIGKLETLTIIRLHLIPQFFLFDLSSIYSLTERVKRTIENSKVFLVPCLLSQHLKSEYLDLSENLMVEEYLKNSACEGAWPFLQTLILRQNHLSLEKTGETLLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
hTLR2	NGVGNFRASDNDRVIDPGKVEVTLTIIRLHLIPQFFLFDLSTLYSLTERVKRTIENSKVFLVPCLLSQHLKSEYLDLSENLMVEEYLKNSACEGAWPFLQTLILRQNHLSLEKTGETLLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
cmTLR2	NGVDFRGSNDRVIDPGKVEVTLTIIRLHLIPQFFLFDLSTLYSLTERVKRTIENSKVFLVPCLLSQHLKSEYLDLSENLMVEEYLKNSACEGAWPFLQTLILRQNHLSLEKTGETLLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
dTLR2	YGLGDFDIPDVKIKNIQIETLTVRRHLHIPHFYSFYDMSIYSLTEDVKRTIENSKVFLVPCLLSQHLKSEYLDLSENLMVEEYLKNSACEGAWPFLQTLILRQNHLSLEKTGETLLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
raTLR2	NGVDFEVPDRDLSQLGKVEVTLTIIRLHLIPQFFLFDLSTIYSLSERVKRTIENSKVFLVPCSPQHLKSEYLDLSENLMVEEYLKNSACEGAWPFLQTLILRQNHLSLEKTGETLLTLKLNLLDLSKNNFLSMPETCQWPERLR					
mTLR2	NGLGDFNPESDVSVELGKVEVTLTIIRLHLIPQFFLFDLSTIYSLSERVKRTIENSKVFLVPCSPQHLKSEYLDLSENLMVEEYLKNSACEGAWPFLQTLVLSQNHLSMQKGTGELLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
rTLR2	NGVGNFNPESDVSVELGKVEVTLTIIRLHLIPQFFLFDLSTIYSLSERVKRTIENSKVFLVPCSPQHLKSEYLDLSENLMVEEYLKNSACEGAWPFLQTLVLSQNHLSMQKGTGELLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
chTLR2	NGVGFQNPESDVSVELGKVEVTLTIIRLHLIPQFFLFDLSTIYSLSERVKRTIENSKVFLVPCSPQHLKSEYLDLSENLMVEEYLKNSACEGAWPFLQTLILRQNHLSLEKTGETLLTLKLNLLDLSKNNFLSMPETCQWPGKMK					
cTLR2.1	EGKGAWDMTEIARSKQSS—IETLSITNMTILDYFLFFDLEGLETQVGLKRLSIASSKVFMPVCLARYPSSLLYLDPHDNLVNNRGETICEDAWPFLQTLNLSKNSLKSQAARYISNLHLNLDISENNFGETPDMCEWPNLK					
cTLR2.2	LGTGKWKYQIHANQSQS—LRILTIENLSIEEFYLFDTLQSLDLDLFRKVTVENTKVFVPCLLSQHLKSEYLDLSENLMVEEYLKNSACEGAWPFLQTLNLSKNSLKSQAARYISNLHLNLDISENNFGETPDMCEWPNLK					
	LRR16 xLxLxxNxL	LRR17 LxxLxLxxNxL	LRR18 LxxLxLxxNxL	LRR19 LxxLxLxxNxL	LRR20 LxxLxLxxNxL	
bTLR2	QLNLSSTRIHSLTQCLPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISRNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALGRVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRAA					
nTLR2	QLNLSSTKIRSLTQCLPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISRNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALGRVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRAA					
dwbTLR2	QLNLSSTRIHSLTQCLPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISRNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALGRVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRAA					
gTLR2	QLNLSSTRIHSLTQCLPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISGNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALARVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRAA					
pTLR2	YLNLSSTRIHSLTQCLPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISRNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALAQVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRTA					
hoTLR2	YLNLSSTRIHSLTQCLPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISRNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALDQVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRTA					
hTLR2	YLNLSSTRIHSGTICPKTLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISRNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALAKVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRTA					
cmTLR2	YLNLSSTRIHSGTICPKTLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISRNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALAKVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRAA					
dTLR2	YLNLSSTRIHSGTICPKTLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISRNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALAKVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRTA					
raTLR2	RLNLSSTRIHSLTQCLPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRISRNINTPFSKEQLDSFPQKLKLEAGGNFICSCDFLSFTQGGQALTRVLDVWPDYRCDSPSHVRGQRVQDARLSSECHRAA					
mTLR2	FLNLSSTGIRVVKTCIPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRIRENAVSTPFSKQDLSGFPKLELEAGDNHFVCSCELLSFTMETPALAQVLDVWPDYRCDSPSHVRGQRVQDARLSSECHQAA					
rTLR2	FLNLSSTGIQAVKTCIPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRIRENAVSTPFSKQDLSGFPKLELEAGDNHFVCSCELLSFTLHPALVQVLDVWPDYRCDSPSHVRGQRVQDARLSSECHQAA					
chTLR2	FLNLSSTGIQAVKTCIPQTLLEILDVSNNNLDSFSLILPQLKELYISRNKLTLPDASFLPVLVSMRIRENAVSTPFSKQDLSGFPKLELEAGDNHFVCSCELLSFTLHPALVQVLDVWPDYRCDSPSHVRGQRVQDARLSSECHQTL					
cTLR2.1	YLNLSSTQIPKLTTCIPSTLEILDVSNANLQDFGLQPLFLKELYLTKNHLKTLPEATDIPNLVAMSISRNKLSNFSKKEEFPKQMLLDASANNFICSCDFLSFTIHEAGIAQVLDVWGPESYICDPSLTVRGAQVGSVQLSMECHRSL					
cTLR2.2	KYLNLSSTQIPKLTTCIPSTLEILDVSNANLQDFGLQPLFLKELYLTKNHLKTLPEATDIPNLVAMSISRNKLSNFSKKEEFPKQMLLDASANNFICSCDFLSFTIHEAGIAQVLDVWGPESYICDPSLTVRGAQVGSVQLSMECHRSL					

**Figure 3**  
The multiple sequence alignment of LRRs within mammalian TLR2 from 14 species. This panel continued from Figure 2 shows the sequences from LRR11 to the C-termini.

the 20 LRRs [57]. Conversely, zebrafish TLR2 has one additional LRR at the N-terminus, as does Takifugu rubripes TLR1. This *TLR1* family shows a feature that irregular LRRs mainly concentrate at the central part of the LRR domain. In the *TLR3* family, mammalian, Takifugu rubripes and Zebrafish TLR3 contain 25 LRRs as was confirmed by the crystal structure of human TLR3 [52,53]. However, Japanese flounder TLR3 [57] contains two additional LRRs. Similarity sequence search indicates that TLRs from rainbow trout, Atlantic salmon, and goldfish are very similar to Japanese flounder TLR3. TLR4 that constitute the *TLR4* family contains 23 LRRs. Fourteen of the 23 LRRs are similar to "typical". Seven LRRs are irregular. As seen in the *TLR1* family, 5 of the 7 irregular LRRs are in the central part of the LRR domain. Dog TLR4 [Q8SQH3] [56] and human TLR4 variant [Q5VZ17] are shorter by about 200 amino acids at the N-terminus. These two TLRs contain only 16 LRRs. It is also predicted that dog TLR4 has no transmembrane region (Figure 7). TLR5 contains 22

LRRs. Ten of these 22 LRRs are clearly "typical". LRR15 in mammalian TLR5 is only 19 residues (Figure 7); the homolog in Takifugu rubripes and rainbow trout is 24 residues long. The *TLR11* family contains 24–27 LRRs. Most of LRRs in mouse TLR11, TLR12, and TLR13 are "typical". The same feature is observed in Takifugu rubripes TLR21, TLR22 and TLR23. Two Japanese lamprey TLRs appear to belong to the *TLR1* family.

The *TLR7* family consists of TLR7, TLR8 and TLR9 and contains 27 LRRs. Cross dot plots were computed for all of TLR7, TLR8, and TLR9 from human and mouse, and green puffer TLR. More important the super-motif is about 80 residues. Superposition of 21 ((7 × 6)/2) cross dot-plots for the seven proteins emphasize the super-repeat of LRRs at the N-terminal part of the LRR domain (Figure 11) [11]. This super-motif comes from nine LRRs from LRR1 to LRR9 in TLR7 and TLR8, and from eight LRRs from LRR2 to LRR9 in TLR9 (Figure 12). The sequence align-

	LRR1			
Cons	LxxLxLxxNxL			
Seq.	MPHTLMVWVGLVGIISLSKESSNQASLSDCRNGICRKGSSGLNSIPSGLTEAVKSLDLSNRRITYISN			
Proteus	Cchhhhhhhhhhhhhcc			
SSpro4.0	Chhhhhhhhhhhhhhhccch			
	LRR2	LRR3	LRR4	
Cons	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL	
Seq.	SDLQRCVNLQALVLTSGNGINTIEEDSFSSLSGLEHLDLDSYNYLSNLSWFKPLSSLTFNLNLLGNPKYT			
Proteus	cc			
SSpro4.0	llhhcc			
	LRR5	LRR6	LRR7	
Cons	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL	
Seq.	LGETSLFSLTKLQLTRLVGMDFTFKIQKDFAGLTFLEELEIDASDLQSYEPKSLKSIQVSHLILHM			
Proteus	cc			
SSpro4.0	Ccchhhcc			
	LRR8	LRR9		
Cons	NxL	LxxLxLxxNxL		
Seq.	KQHILLLLEIFVDVLTSGVECLERLDTDLDTLHFFSELSTGETNSLTKKFTFRVTKITDESDFQVMKLLNQI			
Proteus	Ecc			
SSpro4.0	Ccc			
	LRR10	LRR11	LRR12	
Cons	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL	
Seq.	SGLLELFDFDCTLGVGNGFRASDNDRVIDPGKVFETLIRRLHPRFVLYFDLSTLYSLTERVKRITVEN			
Proteus	cc			
SSpro4.0	cc			
	LRR13	LRR14		
Cons	NxL	LxxLxLxxNxL		
Seq.	SKVFLVPCLLSQHLKSLYELDLSENMLVEEYLKNSACEDAWPSLQTLRLQNHASLEKTGETLLTKN			
Proteus	Ccc			
SSpro4.0	Ccc			
	LRR15	LRR16	LRR17	LRR18
Cons	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL	LxxLxLxxNxL
Seq.	LTNIDISKNFPHISMPETCQWPEKMKYLNLSSTRHISVTGCTPKTLELDVSNNNLNLPSLNLPQLKELY			
Proteus	Ecc			
SSpro4.0	Ccc			
	LRR19	LRR20		
Cons	LxxNxL	LxxLxLxxNxL		
Seq.	ISRNKMLTPDASLLPMLLVKISRNAITTFKSKEQLDSFHTLKTLEAGNGNFCISCEFLSFTQEQQALA			
Proteus	Ecc			
SSpro4.0	Ccc			
Seq.	KVLIDWPANLYCDSPIHVGQVQVDRVLSVECHRITALVSGMCC			
Proteus	Ccc			
SSpro4.0	llcc			

**Figure 4**  
The secondary structure prediction of human TLR2 by SSpro4.0 and Proteus. The signal peptide and extracellular domain of hTLR2 [O60603] with 784 residues is shown; residues 1–588. The highly conserved segment of individual LRRs is highlighted by a shadow. Abbreviations: h, helix; c, coil; e, β-strand.

ment reveals two types of LRR, S and T. The type S LRR is observed in the first, fourth, and seventh of the 9 tandem LRRs. All other LRRs are type T. Although the third, the sixth and the seventh LRRs is longer than the second, the fifth and the eighth LRRs, their C-terminal VS parts keep the pattern of LxxxxFxxLxx that is seen in "typical" motif. Consequently their LRRs are type T. Thus, there are three super-repeats, *STTSTTSTT*, in TLR7 and TLR8, and two and two-third super-repeats, *TTSTTSTT*, in TLR9. Green puffer TLR forms two horseshoe domains of LRRs. The first domain is homologous to the TLR7 family and thus contains also the super-repeat of *STTSTTSTT* (Figure 12). LRR15 located at the central part of the 27 LRRs consists of long amino acid sequence with 73 residues in TLR7, 64 in TLR8, and 58 in TLR9, as seen in TLR15. This long LRR motif is observed in chicken TLR15. In all the case the next LRR, LRR16, is an irregular LRR that is described by (G/

N)xLxLxxNx(I/L)xxVxxxxFxxLxx is similar to "typical" motif, although position 1 in the HCS part is not occupied by leucine.

**Two cysteine clusters flanking the LRR domain**

The LRRs within most of TLRs are flanked by two cysteine clusters, each of which contains two to five cysteine residues (Table 2 and Figures 5, 6, 7, 8, 9, and 10). Here the cysteine clusters on the N- and C-terminal sides of LRRs are termed LRRNT and LRRCT, respectively [58]. The N-terminal cluster usually consists of two cysteines, C<sub>x5-14</sub>C, but sometimes 3, 4 or 5 cysteines. With high frequency, as noted, the last cysteine of the clusters occupies a structurally equivalent position to those of leucines in the HCS part of LRR1. The C<sub>x8</sub>C motif in TLR3 and the C<sub>x10</sub>C motif of TLR4 form a disulfide bond [52,59], as does the C<sub>x12</sub>C motif in GPIbα [41]. The C<sub>x5-14</sub>C motifs presumably form disulfide bonds. The C-terminal clusters, excepting those in three TLRs (Table 2), contain four cysteines consisting of C<sub>x</sub>C<sub>x22-25</sub>C<sub>x15-20</sub>C. The spacing between the first and the second cysteine that are contained in the last LRR is the same for all the families. The other spacing appears to characterize each family. The C<sub>x</sub>C<sub>x25</sub>C<sub>x18</sub>C motif in TLR3 forms two disulfide bonds between the first and the third cysteines, and between the second and the fourth cysteines [52]. Such pairs of disulfide bonds have been observed for the C<sub>x</sub>C<sub>x20</sub>C<sub>x21</sub>C motif in Nogo receptor [38,39] and the C<sub>x</sub>C<sub>x20</sub>C<sub>x19</sub>C motif in Slit [49]. The disulfide bond connectivity can be inferred for TLRs. The C-terminal cluster for primate TLR4 (C<sub>x</sub>C<sub>x23</sub>C<sub>x17</sub>-C) is different from that of other mammalian TLR4 (C<sub>x</sub>C<sub>x23</sub>C<sub>x18</sub>C). Only in rainbow trout TLR5 and Takifugu rubripes TLR55 having no TIR domain, does the C-terminal cluster consists of two cysteines. There are no N-terminal cysteine clusters in TLR1, TLR6, TLR10, TLR15, and dog TLR4. However, the N-terminal amino acid sequence flanking the LRR domain might form a capping structure.

**Discussion**  
**LRRs within human TLRs**

The present analyses of LRRs within vertebrate TLRs indicate that there are at least two types of LRR motifs; "typical"; "T", LRR, LxxLxLxxNxLxxLxxxxFxxLxx and "bacterial"; "S", LRR, LxxLxLxxNxLxxLPx(x)LPxx. Vertebrate TLRs contain 16–28 LRRs (Table 2 and Figures 5, 6, 7, 8, 9, and 10). Bell *et al.*, [60] have proposed that the ECDs of human TLRs comprised 19–25 LRRs including both "T" and "S" LRRs. Each member of human TLRs contain 1–2 times less LRRs than those identified here. Furthermore, in the TLR1 family (TLR1, TLR2, TLR6 and TLR10) the LRRs at the central parts are aligned differently to each other. Such a difference is also seen in TLR4, TLR5, and TLR7. The alignments of TLR3, TLR8 and TLR9 are nearly identical except the first LRR at the N-terminus of the LRR domain and the last LRR at its C-terminus.



(1) The *TLR1* family

**hTLR1**  
 SIGNAL MTSIFHFAIIFMLLQIRIQLSESEFVDRSKNGLIHVPKD  
 LSQL  
 LxxLxLxxNXL  
 LRR1 TTILNLSQNYI SELWTSDLSSLK  
 LRR2 LRILITSHNR1 QYLDISVFKFNGE  
 LRR3 LEYLDLSHNKL VKIS:HPVTN  
 LRR4 LKHLDLSPNAF DALP1:KEFGMSQ  
 LRR5 LKFLGLSTTHL EKSSVLP1AHLNTS  
 LRR6 KVLVLGETYG EKKEPEGLQFN  
 LRR7 TSSLHIVPTN KEFHFLLDVSRYT  
 LRR8 VANSLELSNFK VLEDNKSYFLSLAKLQTNPK  
 LRR9 LSSLTANMET TNSFIRILQLVHHT  
 LRR10 VVYFVSIKVL QQLDFRDFDYSGETS  
 LRR11 LKALSIIHQVYS DVFGFPQSYIYEIYSMN  
 LRR12 IKNFTVSGTRM VIML:PSK1SP  
 LRR13 FLHLDFSNL TDTVFN:GHLE  
 LRR14 LETLILQMNKL KESK1AEMTTQMS  
 LRR15 LQQLDISQNSV SYDEKGD:SWTKS  
 LRR16 LLSLNMSSNL TDTLFR:LPPR  
 LRR17 IKVLDLHSNKL KSIPIKQVVKLEA  
 LRR18 LQELNVAFNSL TDLPG:GSFSS  
 LRR19 LSVLIIIDHNSV SHPSADFQSG:QR  
 LRR20 MRSIKAGGNPF Q:TELEGFVKNI  
 LRRCT DQVSSEVLGEWPSYK:DYPSYRGTLKDFHMSLS:NT  
 TRANS LLIVTIGATMLAVTVTSL:  
 CYTOP IYLDLPWYLRMVIQWTRRRARNIPLLELQRNLQHFHAFIS  
 VSGHDSFWKSELVPLKLEGGKQILHERNFVPGKSIYENI  
 NIIN TEKSYKSIYVLSNPNFQSEW:HYELYFAHNLPHGEGS  
 NNLILILEP1PQSIIPNKHKLKALMARTYLEWPKKSKR  
 GLFWANRAAINRLTEQAKK

**jfTLR2**

SIGNAL MQQMIPLFTLLPLLSSLGGGS  
 LRRNT SNPGRFS:RS:DLHLS:D:SRGQFTHVPIVTSR  
 LxxLxLxxNXL  
 LRR1 ALTLDSFNNT TMVTDVLTGHER  
 LRR2 LRTLDSHGVRV AGHPAADFSLWS  
 LRR3 LEELDLSHNQL TSLNPDWFQELGA  
 LRR4 LLRLNLHNPY RCVGSSPVFHLVR  
 LRR5 LRRLAFGGPAL EEIKMAALSGVTE  
 LRR6 LETLTVHANNL SSGPFLTNMALASVLRDVSYPETPIV  
 LRR7 LEDLHLIGNRS TQPLRELARR  
 LRR8 VRNMTFRNLSV SDEATVSVIEILDGVP  
 LRR9 LTYFSIDGVTL TGEGRWEKASWADFHS  
 LRR10 IDEFFIQQIVV LDVRFVYSLRLKFLAQ  
 LRR11 PRKSVINSRM FVLPDQTFLLKSS  
 LRR12 LQVLDLSDNL TDMTLVETLCSKRCALKD  
 LRR13 LRVNLISGNAL KSLSTLSRLVERLHK  
 LRR14 LTHLDISNRY SSMPSGCSWPST  
 LRR15 LRVNLISGAKL TTITPCLPKT  
 LRR16 LEVLDLSDNL QGVVALPA  
 LRR17 LRELRLSGNKL LRLPPGSPWPN  
 LRR18 LQTLTVQSNLT NMFDRDLRSFPR  
 LRR19 LQNLQAGQVRL VCTDFVAFQSS  
 LRRCT IRGDEIVRLTDEESYICDPSFLLQGEPPQIYLSFVLCRRD  
 TRANS LVVIVVAATFVVLILVLI  
 CYTOP LPVSLCGVALVGVILCVLLWRLHAWYLRMMWAWLRKHS  
 SRRRLRNLRESEALLSVDYAFVSYEKDAGWVETLVPELEE  
 PRETDEDSVHNDPRPLTLCHKROPLGHWIMDNLMSAMER  
 SRRYTVVLSQNFVQSDWCRVELDFSHFWLFDGDFRGEPAILI  
 LLEPLSKDVPKRFCKLRKMLSSYTYLEWQEEERGEFWRK  
 LRSALRGDGEDEE

**hTLR2**

SIGNAL MPHTLMMVYLVGVIISL  
 LRRNT SKEESSNQASLS:DRNGI:RGSSGSLNS1PSGLTEA  
 LxxLxLxxNXL  
 LRR1 VKSLDLSNRI TYISNSDLQR:VN  
 LRR2 LQALVLTNSGI NTIEEDSPSSLGS  
 LRR3 LEHLDSLNYL SNLSSWFKPLSS  
 LRR4 LTFLLNLGNPY KTLGETSLFSLTK  
 LRR5 LQILRVGNMDF FTKIQRKDFAGLTF  
 LRR6 LEELEIDASDL QSYEPKSLKSIQN  
 LRR7 VSHLILMRQH ILLLEIFVDVTS  
 LRR8 VE:LELRODLD DTFHSELSTGETNSL  
 LRR9 IKKFTFRNVI TDESLLQWMLLNQISG  
 LRR10 LLELEFDD:TL NGVGNFRASDNDRV1DPGK  
 LRR11 VETLITRRHLH PRFVLYDLSLTYLSTER  
 LRR12 VKRTITNSKV FLYPLLSQRLKS  
 LRR13 LETLDSLNL VEEYLNKNSA:EDAWPS  
 LRR14 LQTLILRQHL ASLEKTGETLLTLKN  
 LRR15 LTNIDISKNSF HSMPTI:QWPEK  
 LRR16 MXYLNLSTR1 HSYTG:1PKT  
 LRR17 LEILDVSNL NLFSLNLQ  
 LRR18 LKELYISRNKL MTLPDASLLPM  
 LRR19 LLVLKISRNL1 TFSKELDFSHF  
 LRR20 LKTLAAGGNF I:CS:EFLSFTQEQ  
 LRRCT QALAKVLDWPNYLDSPSHVRGQVQVRLSVSE:1HRTA  
 LVSQMC  
 TRANS ALFLILLTGVLC  
 CYTOP HRFGHLYMAMWALQARRKPRKPSRNL1YDAFVYSER  
 DAYWYVNLVQLEENFPNPKL:1LHRDFIPGKWI1DNI1D  
 SIEKSHKTVVLSNPNFQSEW:HYELDFSHRFDENNDAA  
 ILILEP1EKA1PQRF:KLRKIMNTKTYLEWQEEERGEFWRK  
 GLFWANRAAINRLTEQAKK

**hTLR6**

SIGNAL MTKDEP1VKSFFVCLM111VGTRIQPSDGNFVADKSKRG  
 LHRPKDLPLK  
 LxxLxLxxNXL  
 LRR1 TKVLDMSQNYI AELQVSDMSLSE  
 LRR2 LTVLRLSHNR1 QLDDISVFKFNQD  
 LRR3 LEYLDLSHNQL QKIS:HPIVS  
 LRR4 FRHLDSFNDF KALP1:KEFGNLSQ  
 LRR5 LNFLGLSANKL QKLDLPIAHLHS  
 LRR6 YLLDLRNYI KENETESLQILNAK  
 LRR7 TLHLFVHTSL FAIQVNSVNT  
 LRR8 LG:LQTLN1KL NDN:QVF1KPLSELTRG  
 LRR9 PTLNFTLNH1 ETTW:LVRVQFVWPKP  
 LRR10 VEYLNLYNLT1 IESIREEEDTYSKTT  
 LRR11 LKALTEH1TN QVPLFSQALYTVSEMN  
 LRR12 IMMLTISDTPP IHML:PHAPST  
 LRR13 PKFNFQVFP TDS1FEK:SLTVK  
 LRR14 LETLILQKNGL KDLFKVGLMKDMP  
 LRR15 LETLIDVNSL ESGRHKN:TWVES  
 LRR16 IYVNLSSML TDSVFR:LPPR  
 LRR17 IYVLDLHSNKL KSVYKQVVKLEA  
 LRR18 LQELNVAFNSL TDLPG:GSFSS  
 LRR19 LSVLIIIDHNSV SHPSADFQSG:QR  
 LRR20 MRSIKAGGNPF Q:TELEGFVKNI  
 LRRCT DQVSSEVLGEWPSYK:DYPSYRGSLKDFHMSLS:NT  
 TRANS LLIVTIGATMLAVTVTSL:  
 CYTOP TSL:IYLDLPWYLRMVIQWTRRRARNIPLLELQRNLQHFHAFI  
 F1SYSEHDSAWKSELVPLLEKEDIQILHERNFVPGKSIYENI  
 NIIN TEKSYKSIYVLSNPNFQSEW:HYELYFAHNLPHGEGS  
 NNLILILEP1PQSIIPNKHKLKALMARTYLEWPKKSKR  
 GLFWANRAAINRLTEQAKK

**Figure 5**

Sequence alignment of LRR domains within the six families of TLRs. (1) hTLR1 [Q15399]; hTLR2 [O60603]; hTLR6 [Q9Y2C9]; hTLR10 [Q9BXR5]; tTLR14 [Q5H726]. (2) hTLR3 [O15455]; jfTLR3 [Q76CT7]. (3) hTLR4 [O00204]; dTLR4 [Q8SQH3]. (4) hTLR5 [O60602]. (5) mTLR11 [Q6R5P0]; mTLR12 [Q6QNU9]; mTLR13 [Q6R5N8]; tTLR21 [NP\_001027751]; tTLR22 [Q5H723]; tTLR23 [AAW70378]; (6) hTLR7 [Q9NYK1]; hTLR8 [Q9NR97]; hTLR9 [Q9NR96]. (7) jfTLRa [Q33E93]; cTLR15 [ABB71177]. The complete amino acid sequences are shown for hTLR1 with 786 residues (res.), hTLR2 with 784 res., hTLR6 with 796 res., hTLR10 with 811 res., tTLR14 with 871 res., hTLR3 with 904 res., jfTLR3 with 961 res., hTLR4 with 839 res., dTLR4 with 636 res., hTLR5 with 858 res., hTLR7 with 1049 res., hTLR8 with 1041 res., hTLR9 with 1032 res., mTLR11 with 926 res., mTLR12 with 906 res., mTLR13 with 991 res., tTLR21 with 965 res., tTLR22 with 950 res., tTLR23 with 941 res., jfTLRa with 813 res., and cTLR15 with 868 res., Cysteine is highlighted in magenta. Its boldface indicates cysteines in LRRNT or LRRCT. Residues of missense mutation are highlighted in blue boldface. SIGNAL, signal peptide sequence; LRRNT, the cysteine clusters on the N-terminal side of LRRs; LRRCT, the cysteine clusters on the C-terminal side of LRRs; TRANS, transmembrane region; CYTOP, cytoplasmic region. Abbreviations: h, human; m, mouse; t, Takifugu rubripes; c, chicken; d, dog; jf, Japanese flounder. This panel shows hTLR1, hTLR2, jfTLR2 and TLR6 in the TLR1 family.

**hTLR10**

SIGNAL MRLIRNIYIFCSIVMTAEGDAPELPEERELMTNCNMSLRKV  
 PADLTPA  
 LxxLxLxxNxL  
 LRR1 TTTLDLSDYLL FQLQSSDFHSVSK  
 LRR2 LRVLLILHNRI QQLDLKTFEFNKE  
 LRR3 LRYLDSLNNRL KSVTWYLLAG  
 LRR4 LRYLDSLDFNDF DTMPICEEAGNMSH  
 LRR5 LEILGLSGAKI QKSDFKIAHLH  
 LRR6 LNTVFLGFRTL PHYEBSPLILNTT  
 LRR7 KLHIVLPMMDTN FVWLLRDGIKTSKILEMTNIDGKSQFVSYEM  
 LRR8 QRNLSENAKT SVLLLNKVDLL  
 LRR9 WDDLFLILQFV WHTSVBFHQIRNVTF  
 LRR10 GKKAYLDHNSF DYSNTVMRTIK  
 LRR11 LEHVHFRVFIY QQDKIYLLLTKMD  
 LRR12 IENLTISNAQM PHMLFPNYPTK  
 LRR13 FQYLNFAANNIL TDELFKRTIQLPH  
 LRR14 LKTLILGNKLE ETLSLVSCFANNT  
 LRR15 LEHLDSLQNL QHKNDENCSWPET  
 LRR16 VVMNLSYMKL SDSVFRCLPKS  
 LRR17 IQILLDNQQI QTVPKETIHLMA  
 LRR18 LRELNIAFNFI TDLPGCSHFPSR  
 LRR19 LSVLNIEMNFI LSPSLDFVQSCQE  
 LRR20 VKTLNAGRNF RCTCELKNFQLE  
 LRRCT TYSEVMVWGSDSYTCYEPLNLRGIRLKDVLHELSCNTA  
 TRANS LLIVTIVVIMLVGLAVAF  
 CYTOP CCLHFDLPWYLRMLGQCQTQVHRVRKTTQEQLRKRVRF  
 HAFISYSEHDSLWVKNELIPNLEKEDGSLICLYESYF  
 DPGKISENIVSFIEKSYKIFVLSFNFQNEWHYEF  
 YFAHNLPHNSDHIILILLEPIPFYCIPTRYHKLKAL  
 LEKKAYLEWPKDRRCKGLFWANRAAINVNLATREMY  
 ELQTFTELNEESRGSTISLMRTDCL

**tTLR14**

SIGNAL MIWTFVHFIALAVGLA  
 LRRNT STTPSPSTTKTIVTGC RVFNS  
 LxxLxLxxNxL  
 LRR1 GRSADCLGMQL SSVPRQFPFP  
 LRR2 LEDIDLSDYRL QVINAEDFALFPR  
 LRR3 LRSLLNLYNNI SRIDSDAFKNNPL  
 LRR4 LEILDIFNNSL GEIPVAALPLL  
 LRR5 LKLYMSNNLY KRAALAEPTFVFR  
 LRR6 LQTLSDMGPLV EGLKKGDFQP  
 LRR7 LRKRLRQEFAI KSSNLRYYEAGSLEVVQTKL  
 LRR8 GFDMADQRPS ALVDMRLDIANKT  
 LRR9 FIAIQFRNLFE FRYTYRQDIFQG  
 LRR10 LKHVAAYQLIF HRGKPNENLRMALLNLEA  
 LRR11 IKRLRFQYIDF ARSPTFVDNRAGSSITDLV  
 LRR12 LDKLDELWYISN PDVLRFDWRFTWFNN  
 LRR13 IRSLSIQVYVF NSVPCDSWAEMKQ  
 LRR14 VKVLDVSNRRL TDYIFNQLYNYRGAAPN  
 LRR15 LRLFMSNNEL TSLKDLSLTKEFQQ  
 LRR16 LQELDSLNRKL GSAAESRNITWQKS  
 LRR17 ITRFIVHNNF ESSALHLPTS  
 LRR18 VEFLLDSFCDL DQLDMNYFSKTSN  
 LRR19 LQELHLSGNKI KFIPSKWAAPS  
 LRR20 LQSLSDGNSF GLIGTESFQDMPR  
 LRR21 LSHLSAGNPF HCTCELHAFVQET  
 LRRCT ITEGKVNLDWPNWNYCYHPEPLLNTVISQYLPKVAQDIR  
 TRANS LYIVI CVAATTFVVLILVLI  
 CYTOP C YIFDLPWYTKATFQIIRAKYRAHKEKAAGEEGPFTYH  
 AFISYSHSDADWVRDQLLPCLENNNPYRLCTHERDFT  
 PGRWIDNI LENIENSRKVI FVLSRHFNSEWNYELY  
 FAQQRAMGKTFSDVILVVKEP IDPNLPSKYCKLKKM  
 LSTKTYLEWFPQVQAFQAFWAQLRSVLRGPTAVTRGRQ  
 SVRSRTSSASISVIGPLVDERNPEMEDDEGTETPNYEVI  
 ENSLEVSHQRQIPMVAV

**(2) The TLR3 family**

**hTLR3**

SIGNAL MRQTLPCYFVGWLLPFGMLCAS  
 LRRNT STTKCTVS  
 LxxLxLxxNxL  
 LRR1 HEVADCSHLKL TQVDDLPNTN  
 LRR2 ITVNLNTHNQL RRLPAANFTRYSQ  
 LRR3 LTSLDVGFNTI SKLEPELQKLP  
 LRR4 LKVLNLQHNEL SQLSDKTFACFN  
 LRR5 LTELHLMSNST QKIKNPNPVKQKN  
 LRR6 LITLDLSDYRL SSKLGTQVQLEN  
 LRR7 LQELLSNNKI QALKSEELDFANSS  
 LRR8 LKKELESNNKI KEFSPGFHAIGR  
 LRR9 LFGFLFNVQL GPSLTELKLELANTS  
 LRR10 IRLNLSNSQL STSNTTFLGLKWTN  
 LRR11 LTMLDLSYNNL NVVGNDSFAWL PQ  
 LRR12 LEYFLEYNNI QHLFSLHLGLFN F303S  
 LRR13 VRYLNLKRSFT KQISLASLPKIDDFSFQWLK  
 LRR14 LEHLNEMDNDI PGKSNMFTGLIN  
 LRR15 LKYLSDNSFT SLRNLNETFVSLAHP  
 LRR16 LHILNLTNNKI SKIESDAFVWLGH  
 LRR17 LEVLDLGNEL QGELTQGEWRGLEN  
 LRR18 IFEIYLSYNYK LQLTRNSFALVPS  
 LRR19 LQRLMLRRVAL KNVDSSPFPQLRN  
 LRR20 LITLDLSNNNI ANINDMLEGLEK  
 LRR21 LEILDQLNNL ARLWKHANPGPIY H539E  
 FLKGLSH N541A  
 LRR22 LHILNLESNGF DEIPVEVFKLDFE  
 LRR23 LKIIDLGLNNL NTLPASVFNQVS  
 LRR24 LKSLNLQKNI TSVEKRVGPAFRN  
 LRR25 LTELDMRFNPF DCTESIAWFVWIN  
 LRRCT ETHNIPELSSHVLCNTPPHYHGFVRLFDTSCKDSAPPE  
 TRANS LFFMINTSILLIFIVILLI  
 CYTOP HFEGWRISFYWVNSVHRVLGFKEIDRQTEQFEYAAI I H  
 AYKDKDWWHEHFSMEKEDQSLKFLLEERDFEAGVFELE  
 AIVNSIKRSRKIIFVITHLLKDKPLKRRFKVHVAVQQA  
 EQNLDSIILVFLBEEIPDYKLNHALCRRGMFKSHCILNW  
 PVQKERI GAFRHLQVALGSKNSVH

**jfTLR3**

SIGNAL MGPGGKEDERETGGRKHQVLTFFLLTISL LAPISGFA  
 LRRNT LKTCRIS  
 LxxLxLxxNxL  
 LRR1 YNIAKCKMGL TAAPRDIPSA  
 LRR2 YKGFDSLSENKI LRVLSDFENLPG  
 LRR3 LTQLDLNRNLI SQIDDGAFANLIF  
 LRR4 LKKNLNNKIL VTLGENPHGLSN  
 LRR5 LTELRLMSNGI KAVLTLSFKPMNS  
 LRR6 LKFLDFSHNLI KHITKVSRIQHLPN  
 LRR7 LRELFLKKNDF TTFHSEELTNSLQ  
 LRR8 LKALDLSQNPITDFQITANVFPN  
 LRR9 LTNLNLGGAP KTPVILGVRNKTFFPSR  
 LRR10 VSTLDITGLRM TLVDNRTLLGTVNSS  
 LRR11 LSSLRMAMKN NITALTHISCTIPT  
 LRR12 LSTLHVRHNL TYVSSDLFKLFFN  
 LRR13 IREIDLTDNKI KTRDDAFSSLQS  
 LRR14 LKTLDSLNRKL SSVPYATRTLPS  
 LRR15 LGELDLSFNKI TKLGDFFANQTK  
 LRR16 LRRRLYHNSI ASLAEVFKDLVQ  
 LRR17 LQVLLQNNHL SNLNGAFRDLPN  
 LRR18 LRQLLLNGNL TALKHGEFRGLS  
 LRR19 LQNLSHENKI FNLDKG FVGLTN  
 LRR20 LTDILLQNNKI RETEISKGVFNLDIN  
 LRR21 LRRLELRNHI KYNNSSLPAPESRLSR  
 LRR22 LETLAIPSQHG KGSQPRNLLLEGLN  
 LRR23 LLVFNIRNIQL ASLHKDMFNGTPQ  
 LRR24 LTTLDISSNEL MDLSPDLFSPIPN  
 LRR25 LKSLYVSRSL RSLDYLGTANLTK

1

**Figure 6**

Sequence alignment of LRR domains within the six families of TLRs. This panel continued from Figure 5 shows hTLR10 and hTLR14 in the TLR1 family, and hTLR3 and jfTLR3 in the TLR3 family. .

LRR25 LKSLYVSRISL RSLDYLGTANLTK  
 LRR26 LEFLQARKNEF SIISEEEI IKVSPS  
 LRR27 LYYADFQGNF TCKDNAWF IKWV  
 LRRCT EYNNQTVFDAYNFCNYPLNLKGTLLHFDIRS CSVD  
 TRANS AGFLMFLSTCTLLFML  
 CYTOP TSFTYHFLRWHLAYAYFFLALLFDTKHKNKQPPNQYD  
 APISYNTHDEPWWVRELLPKLEGEQGWRL LHRDLMP  
 GKPIVENIVDAIYGSRRK TICVISRRYLESEW SREMQV  
 ASFRLEDEQKDLILVFLFEDIPTDELSPYYRMKLLNK  
 MSYLSWPRAAHEHTELFWEKLRQALRTREDQADESFRILT  
 VVDNQW

DHRQLLVKVEQMVCAKPLDMKMPLLSFRNATLSEEAR  
 LSISVSVFTVLHGFSGSSRSRYKFFHMLLAWLAKGI  
 TEGKVPMMHFVYISSQDEWVRNELVKNLEEGVPPQL  
 CLHYRDFIPGVAIAANI IQEGFYKSRKVI VVVSQHF IQ  
 SRWCIFEYEAIAQTWQFLSSRAGI IFIVLQKVEKSLLRQ  
 QVELYRLLSRNTYLEWEDSVLGRHIFWRRLLKALLDGK  
 PWSPEGTEDEAKS

**(3) The TLR4 family**

**hTLR4**

SIGNAL MMSASRLAGTLIPAMAF LCVRP  
 LRRNT ESWEPCVEVVP  
 LxxLxLxxNxL  
 LRR1 NITYQMEANF YKIPDNLPFS  
 LRR2 TKNLDLSPNPL RHLGYSFFSPPE  
 LRR3 LQVLDLSR EIT QTI EDGAYQLSH  
 LRR4 LSTLLTGNPI QSLALGAFSGLSS  
 LRR5 LQKLVAVE NL ASLENFPIGHLKT T135A  
 LRR6 LKELVAHNLI QSFKLPYPSNLTN  
 LRR7 LEHLDSL SNKI QSIYCTDLRVLHQMPLL  
 LRR8 NLSLDLSLNP MFIQPGAFKEIR  
 LRR9 LHKLTLRNNFD SLNVMKTIQGLAGLE  
 LRR10 VHRVLGFEFRN EGNLEKFDKSALEGLCNLT  
 LRR11 IEEFRLAYLDY YLDDIIDLFNLTN D299G  
 LRR12 VSSFSLVSVTI ERVKDFSYNFG  
 LRR13 WQHLELVN KF GQFPTLKLK  
 LRR14 LKRLTFTSNKG GNAFSEVDLPS  
 LRR15 LEFLDLSRNL SFRKCCSQSDFGTT S T399I  
 LRR16 LKYLDSL FNGV ITMSSNFLGLEQ  
 LRR17 LEHLDFHNSL RQMSFVSFSLRN  
 LRR18 LIYLDISHTHT RFAFNGIFNGLSS  
 LRR19 LEVLKMGNSF QENFLPDIFTELNR  
 LRR20 LTFDLDSQQL EQLSPTAFNSLSS  
 LRR21 LQVLMSHNMF FSLDTPPYK LNS  
 LRR22 LQVLDYSLNHI MTSKQELQHPFS  
 LRR23 LAFLNLTQDNF ACTCEHQSFQWIK  
 LRRCT DQRQLLVEVERME ATPSDKQAMPVLSLNTICQMNKT  
 TRANS ITIGVSLVSVVAVLV  
 CYTOP YKFFHMLLAGC IKYGRGENIYDAFVIYSSQDEWVR  
 NELVKNLEEGVPPQLCLHYRDFIPGVAIAANI IHEGF  
 HKSRRKVI VVVSQHF IQSRWCIFEYEAIAQTWQFLSSRAG  
 IIFIVLQKVEKTLRQQVELYRLLSRNTYLEWEDSVLG  
 RHIFWRRLLKALLDGKSNWPEGTVCNWEQATSI

**dTLR4**

MPLL  
 LxxLxLxxNxL  
 LRR1 NLSLDLSLNP YFIQPGSFKEIK  
 LRR2 LHKLTLRSNFN STDVMKFTIQS  
 LRR3 LAGLQINQVYL GEFKNERKLESFDNSLLEG  
 LRR4 LNLTIKFR I AYFDSFSKDTNLFNQLVN  
 LRR5 ISATSLAHLYL DTPKYLKPNLR  
 LRR6 WQRLEIVN CNL EQPPAWELDS  
 LRR7 LKEFVLTSNKG MNTFADMKME S  
 LRR8 LEFLDLSRNL SFRKCCSHSDFGTTR  
 LRR9 LKHLDSL FNEI ITMSSNFLGLEQ  
 LRR10 LEYLDLQHSLS RQASDFVSFSLRN  
 LRR11 LRYLDISYTRT EVAFAQIFDGLVS  
 LRR12 LEVLKMGNSF PDNSLPNIYKGLTN  
 LRR13 LTIILDLRCHL ERVYQESFVSLPK  
 LRR14 LQVINMSHNSL LSLDTLAYEPLLS  
 LRR15 LQILD SFNRI VAPKQGGQHPFSN  
 LRR16 LVSLNLT RNSF ACDCHEQSFQWVK

**(4) The TLR5 family**

**hTLR5**

SIGNAL MGDHLDLLLGVVLMAGVPFG  
 LRRNT IPSCSFDGRIAFYRPNLTQVPQVNLN  
 LxxLxLxxNxL  
 LRR1 TERLLLSFN YI RTVTASSFPFLEQ  
 LRR2 LQLELGSQYI PLTIDKEAFRNLPN  
 LRR3 LRILDLGSSKI YFLHPDAFQGLFH  
 LRR4 LFELRLYFGL SDAVLKDG YFRNLKA  
 LRR5 LTRLDLSKNQI RSLYLHPFSGLKNS  
 LRR6 LKSIDFSSNQI FLVCEHELEPLQGT  
 LRR7 LSPFSLAANSL YSRVSDWGC MNPFRNMV  
 LRR8 LEIVDVSNGW TVDITGNFSNAISKSQA  
 LRR9 AFSLLAHHIM GAGPGFHNIKDPQNTFAGLARSS  
 LRR10 VRHLDSLHGFI FSLNSRVFETLKD  
 LRR11 LKVLNLAYNKI NKIADAEFYGLDN  
 LRR12 LQVLNLSYNL GELCSSNYGLPK  
 LRR13 VAYIDLQKNH AI IQDQTFKPLEK  
 LRR14 LQTLDLRDNAL TT IHPIS  
 LRR15 IPDIFLSGNKL VTLPKINLT  
 LRR16 ANL IHLSENRL ENLDILYFLLRVPH  
 LRR17 LQILILNQRNF SSCSGDQTPSENPS  
 LRR18 LEQLFLGNML QLAWETELCWDVFEGLSH  
 LRR19 LQVLYLNHNIL NSLPGVFSHLTA  
 LRR20 LRGLSLNSNRL TVLSHNDLPAN  
 LRR21 LEILDLSRNL LAPNPDVVS  
 LRR22 LSVLDITHNKF ICCEELSTFINWL  
 LRRCT NHTNVTIAGPPADIIYCVYPSDFSGVSLFSLSTEGCDEEE  
 VLKSLK  
 TRNS FSLFIVCTVTLTLFLMTIL  
 CYTOP TVTKFRGCFICRYKTAQRLLVFKDHPQGTPEPMYKYDAYL  
 CFSSKDFWVQNALKHLDTQVSDQNRFNCFEERDFVP  
 GENRIANIQDAIWSRKRIVLSRHRFLRDGWCLEAFSYA  
 QGRCLSDLSALIMVVGSLSQYQMKHQSIRGFVQRQQ  
 YLRWPEDLQDVGFHLKLSQILKJKEKEKKDNNIPLQ  
 TVATIS

**(5) The TLR11 family**

**mTLR11**


SIGNAL MPRMERHQFC SVLLILILLTVLSLTLTGWA  
 LRRNT WTIPDCI IADSLIFPNLSYI PFC TAPGLHLLASC SNV  
 KNLNQTLKRVRP  
 LxxLxLxxNxL  
 LRR1 NTEVLQCGMV PTLPAKAFIRFHSLQ  
 LRR2 LLRLQLRTTSV TSRTFQGLDQ  
 LRR3 LQYLFDDHAP CCLSLFLSPNCFESLRS  
 LRR4 LSSLSFQGYL TYSQSIYLPST  
 LRR5 LRHLTLRNSCL TKFQDLQRL  
 LRR6 FPDLLSSTSST PNIRKPGAPP  
 LRR7 LETLDLSYNLQ LKQAGVRDLYGLT  
 LRR8 LHSLLDGTPL KALDITDSGLLH  
 LRR9 LHFLSLVGTGI EKVPASLTGYSE  
 LRR10 LRALDLGKNQI QNTLENGEIPGYKA  
 LRR11 LEFLSLHDNHL QTLPTFRHLTLTPQ  
 LRR12 LQKLNLSMNL GPILLEPEGLFSTN  
 LRR13 LKVLDSLQNL CDPHGALSLLSQ  
 LRR14 LQELVSGNNT SSSLNESLQGLRQ  
 LRR15 LRITLDSLWNQI KVLKPGWLSHLPA

**Figure 7**

Sequence alignment of LRR domains within the six families of TLRs. This panel continued in Figure 6 shows jfTLR3 (from LRR25 to CYTOP in the TLR3 family, hTLR4 and dTLR4 in the TLR4 family, hTLR5 in the TLR5 family, and mtLR11 (from SIGNAL to LRR15) in the TLR11 family.



**Figure 8**  
Sequence alignment of LRR domains within the six families of TLRs. This panel continued in Figure 7 shows mtTLR11 (from LRR16 to CYTOP), mTLR12, mTLR13, and tTLR21 in the TLR11 family.



1

**Figure 9**  
Sequence alignment of LRR domains within the six families of TLRs. This panel continued in Figure 8 shows tTLR22 and tTLR23 in the TLR11 family, and hTLR7 and hTLR8 (from SIGNAL to LRR12) in the TLR7 family.

LRR13 LRALHLRGYVF QELREDDFQPLMLQPN  
 LRR14 LSTINLGINFI KQIDFKLQNFNS  
 LRR15 LEITYLSENRI SPLVKDTRQSYANSSSFQRHIRKRRST  
 DFEFDPHSNFYHFRPLIKPQCAY  
 LRR16 GKALDLSLNSI FFIGPNQFENLPD  
 LRR17 IACLNLANSN AQVLSGTEFSAIPH  
 LRR18 VKYLDLNNRL DFDNASALTEUSD D543A  
 LRR19 LEVLDLSYNH YFRIAGVTHHELFIQNFTN  
 LRR20 LKVLNLSHNNI YTLTDKYNLESKS  
 LRR21 LVLELVFSGNRL DILLWDDNNRYISIFKGLKN  
 LRR22 LTRLDLSLNRLL KHIPNEAFLNLPAS  
 LRR23 LTELHINDNML KFFNWTLLQQFPR  
 LRR24 LELLDLRGNKL LFLTDSLSDFTSS  
 LRR25 LRTLLLSHNRLL SHLPSGFLSEVSS  
 LRR26 LKHLDLSSNLL KTNKSALTKTTTK  
 LRR27 LSMLELHGPNF ECTCIDGFRWRM  
 LRRCT DEHLNVKIPRLVDVICASPGDQRGKSIVSLELTCVSDVTA  
 TRANS VILFFFITTMVLAALA  
 CYTOP HHLFYWDWFIYNVCLAKVGYRSLSTSQTIFYDAYISYD  
 TKDASVTDWVINELRVHLEESRDKNVLLLEERDWDPLG  
 AIDNLMQSIINQSKKTIVFLTKYAKSWNFKTAFYLALQ  
 RMDENMDVLIIFLLEPVLQHSQYLRLRQRICKSSILQW  
 PDNPKAEGLFWQTLRNVVLTENDSYNNMYVDSIRQY

**hTLR9**

SIGNAL MGFORSALHPLSLLVQAIMLAMTLA  
 LRRNT LGTLPALPCLELQP  
 LxxLxLxxNxL  
 LRR1 HGLVNCWLF KSVPHFMAAPRGN  
 LRR2 VTSLSLSSNRLL HHLHDSDFAHLPS  
 LRR3 LRHLNLSKWNCP PVGLSPMHFP HMTIEPSTFLAVPT  
 LRR4 LEELNLSYNNI MIVPALPKS  
 LRR5 LISLSLSTHNI LMLDSASLAGLHA  
 LRR6 LRFLEMDGNY YKNPQALEVAPGALLGLGN  
 LRR7 LTHLSLKYNNL TVVPRNLPSS  
 LRR8 LEYLLLSYNRI VKLAPEDLANLTA  
 LRR9 LRVLDVGGNRC RDHAPNPMERPHFPQLHPDTSFHLRSR  
 LRR10 LEGVLKDSLS SWLNASWFRGLGN  
 LRR11 LRVLDLSENFL YKTIKTKAFQGLTQ  
 LRR12 LRKLNLSFNQY KRVSFHLSLAPSFGSLVA  
 LRR13 LKELDMHGIFFF RSLDETTLRPLARLPM  
 LRR14 LQTLRLQMNFI NQAQLGIFRAFFG  
 LRR15 LRYVDSLNRRI SGAELATMGEADGGEKVVLPQGDLL  
 APAPVDTSPSEDFRPNCSL  
 LRR16 NFTLDSLRRNLL VTVQPEMFAQLSH  
 LRR17 LQCLRLSHNCI SQAQVNGSQFLPLTG L499P (in mouse)  
 LRR18 LQVLDLSHNKL DLYHEHSFTLPR  
 LRR19 LEALDLSYNSQ PFGMQGVGHNFSPVAHLRT  
 LRR20 LRHLSLAHNNI HSQVSQLSTS  
 LRR21 LRALDFSGNAL GHMWAEGDLYLHFFQGLSG  
 LRR22 LITWLDLQNRLL HTLLPQTLRNLNPKS  
 LRR23 LQVLRRLRDNYL AFFKWSLHFLPK  
 LRR24 LEVLDLAGNQL KALTNGLSPAGTR  
 LRR25 LRRLDYSNCSI SFVAPGPFSAKAKE  
 LRR26 LRELNLSANAL KTVDHWFGLASA  
 LRR27 LQILDVSNPL HCAGAAMDFLL  
 LRRCT EQAAVPLGPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWD  
 TRANS CFALSLLAVALGLGVPM  
 CYTOP HHLGWDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFV  
 VFDKTSQAVADWVYNELRGQLEERGRWALRLCLEERDWD  
 LPGKTLFENLWASVYGRKTLFVLAHTDRVSGLLRASFL  
 LAQQRLLLEDKDDVVLVILSPDGRRSRYVRLRQLRQS  
 VLLWPHQPSGQRSFQAQGMALTRDNHFFYNRNFCQGPATAE

**(7) Others**

**jTLRa**

SIGNAL MAGWPGMFVAAVLLCLPHPGSC  
 LRRNT VRGEAFFLGRQCSVV  
 LxxLxLxxNxL  
 LRR1 GDVADCSRRL SAVPSGLPSS  
 LRR2 IAQLDLSHNRLL ESLLANDFSDVPL  
 LRR3 LRVLNLSFNRY RDIHPGALAHTAL  
 LRR4 LQHLDLYHNEL LEIPAEAVGNLRL  
 LRR5 LQVLSLANNY TSFVLGGAFANLHS  
 LRR6 LRSLTIGTART DVLNASDFTALQNVN  
 LRR7 VTHLNVHTGSPML MKFEPGVFAFFKM  
 LRR8 LQSFRRMFTVD DDPVIFSKVLLDLNKT  
 LRR9 VSEFQDRVLL NPVKNSIDFFYGLEKCSL  
 LRR10 LRNLTLVAANF TDQETSLKLVVLSQ  
 LRR11 ITSVEITNSY TDRNVVDFGLKLVTKLSP  
 LRR12 LEKVTINQIFH LNMITYPKFAINFTLFP  
 LRR13 FSKLKSHTGM NKVCECFMCLKF  
 LRR14 ITWLDLSSNLL DEBGLWNTCKYTIILPR  
 LRR15 TTELYISNKF TDLQISSMVSMLPS  
 LRR16 ITLLDVGNYI TDIDCSWPT  
 LRR17 LETLILRNDI SKDRSICSPQ  
 LRR18 LKVLDSLTYRM EAVPYILDDAKS  
 LRR19 LRELVLGANNI HYIQPEIQSS  
 LRR20 LQVLDVYNTL GIITKGTQQLPK  
 LRR21 IRALKGNLFCYMDLYWFRQTF  
 LRRCT DKSLLVDWPKYVSYNENLAETLDFNPSIVSCDKRIA  
 TRANS IGLSVVITAVVVALVGLGYFF  
 CYTOP DAVVYIRMGWVWAKRRGYKHVTSGEAPPFEYNAFISYS  
 HMDSDWVEGTLVPLRENSGSLKCVHERDPTGGEWVVDN  
 IIRCEGSSKTLFVLSSTNFVKSWECHYELVFAQHRIMEQH  
 QDLSVLLVLESPLKNSLKNKRLRLLNRKTYLEWPAEE  
 SKQAIFWASLQAILLTSSPTNPVT

**cTLR15**

SIGNAL MRILIGSLYFYFISFLFSKVG  
 LRRNT FLTQRTSPVSSFPFYNNYSYLNLSVSSQAQAPKT  
 LxxLxLxxNxL  
 LRR1 ARALNFSYNAI EKIKTRDFEPGFH  
 LRR2 LEVLDLSHNRI KDIEPGAFENLIS  
 LRR3 LVSVDLSFNDK NLLVSGALPHLKL IPTSGASGSQIYMYFQ  
 KSAEAALEPSAPAEHLPHLEDPNPNPNNVNP  
 RFRQRRTENKTSPPAATLRPDLGAPI  
 LRR4 NGLLDLSRTKL SNEELTAKLDADLQAQGLT  
 LRR5 VLEFNISHSLL EMDLISLFLFLPMKD  
 LRR6 IQSVDSYNRLL TINNIDVEALCHFPFNS  
 LRR7 FSFLNISNNLI NSLETVCLPAS  
 LRR8 ITVIDLSFTNI STIPANFAKLSK  
 LRR9 LERMYVQGNQL IYTVRPNPSPATPRPPGTVQ  
 LRR10 ISALSVRNQA GTPLESLES  
 LRR11 VKHLKVSNSI VELPEWFANRMQE  
 LRR12 LFLDLSSNRI SMLPDLPTIS  
 LRR13 LQQLDISNSDI KIIPPRFKLSN  
 LRR14 VTVFNIQNNKL TEMHPEYFPST  
 LRR15 LTTCDISKNKL KVLSTKALEN  
 LRR16 LESLAVSGNLI TRLEPAQLPS  
 LRR17 LTNLDSHNL SELPDHLGQSLM  
 LRR18 LKHPNLSGKNI SFLQRGSLPAS  
 LRR19 LEELDSDNAL TTIVQDTFGQLTS  
 LRR20 LSVLTVQGHF FUNDLYWVFNII  
 LRRCT IRNPHLQINGKDDLRC SFPPDRRGSVLRKSNLTLHC  
 SLG IQMAITAC  
 TRANS MAILVVVLVLTGLCW  
 CYTOP RFDGLWYVRMGWYMAKRRQYKRPENKPFDAFISYSEH  
 DADWTKEHLLKLETGDKFCYHERDFKGGHPLVGNIFYC  
 IENSHKVLVLPFVNSCWQYELVFAEHRVLDENQDLSI  
 MVVLEDLPPDSVPQKPSLRLKLLKRRKTYLKWPEEHRQKI  
 FWHQLAAVLKTTNEPLVRAENGPNEVIEME

**Figure 10**

Sequence alignment of LRR domains within the six families of TLRs. This panel continued in Figure 9 shows hTLR8 (from LRR13 to CYTOP) and hTLR9 in the TLR7 family, and jTLRa and cTLR15.

### One or two horseshoe domains of LRRs within TLRs

The *TLR7* family (TLR7, TLR8, TLR9 and green puffer TLR) have 27 LRRs and an additional 58–73 residues at the end of LRR15 (Figures 9, and 10). Such a long region is also observed in chicken TLR15 (Figure 10). Gibbard *et al.*, [61] have considered two horseshoe domains of LRRs for human TLR8. That is, LRR15 has been separated into an LRR motif and 40 residues of undetermined structure. Most of the known LRR structures have a cap, which shields the hydrophobic core at the N- and C-termini of LRRs. We suggest that these 40 residues function as the cap of the horseshoe structure, an intervening of hydrophobic core of LRR with a specific feature in TLRs. Thus, it can be concluded that the LRRs in vertebrate TLRs form one or two distinct horseshoe structures. Future structure determinations should resolve the question.


The *TLR1* family (TLR1, TLR2, TLR6, and TLR10) and the *TLR4* family share a common feature, the central part of the LRR domain has a more irregular motif compared with those at the N- and C-terminal parts. The LRR structure in the three families of *TLR1*, *TLR4* and *TLR7* might show a structural flexibility at the central part. Alternatively, the central part would play a key role in the function.

### The LRR arc of TLRs is flat?

The LRR arc structures can be characterized by three parameters- the inner radius of the arc ( $R$ ), the mean rotation angle about the central axis relating one  $\beta$ -strand to the next ( $\bar{\varphi}$ ), and the tilt angle of the parallel  $\beta$ -strand direction per turn ( $\theta_t$ ). A 3D circle fitting method to calculate these geometrical parameters has been developed [55]. The TLR3-LRR arc yields  $R = 26.5\text{--}26.6\text{\AA}$ ,  $\bar{\varphi} = 10.8\text{--}10.9^\circ$  and  $\theta_t = 24.5\text{--}26.7^\circ$ . The TLR3-LRR belongs to "typical" type. This  $R$  value is comparable to 22–36  $\text{\AA}$  for the LRR arcs in Slit, FSHr, nogo receptor, decorin, and GPIIb $\alpha$  with "typical" LRRs [8,55,58]. In contrast, the  $\theta_t$  value is comparable to only those for Slit ( $-21^\circ$ ) and FSHr ( $-40^\circ$ ). Also the  $\theta_t$  value corresponds to 19–40 $^\circ$  for ribonuclease inhibitor and 15 $^\circ$  for tropomodulin with "RI-like" LRRs. That is, the TLR3-LRR arc is nearly flat. This indicates that all other TLRs except for the *TLR7* family and TLR15 might adopt flat LRR arc.

### Super-motif of LRRs in the TLR7 family

The present analysis reveals that the *TLR7* family consisting of TLR7, TLR8 and TLR9 and green puffer TLR contains the super-motif consisting of *STT*. Such super motifs have been observed in various LRR proteins [8,11]. One of them is the SLRP family. The SLRP family forms five distinct subfamilies. Class I consists of biglycan, decorin, and



**Figure 11**

Super-repeat of LRRs in the *TLR7* family of TLR7, TLR8 and TLR9. Forty-two superimposed, cross-dot matrices from human TLR7 [Q9NYK1], mouse TLR7 [P58682], human TLR8 [Q9NR97], mouse TLR8 [P58682], human TLR9 [Q9NR96], mouse TLR9 [Q9EQU3], and green puffer TLR [Q4S0D3] with the window size of 21 residues and the stringency of 10 (upper) and with the window size of 41 residues and the stringency of 20 (lower). The summed scores for the 21 ( $(7 \times 6)/2$ ) comparisons are represented by color. The order of higher scores is red > purple > blue > light blue. Residue 46–291, 46–291, 44–288, 44–283, 40–285, 40–285, and 23–268 of human TLR7, mouse TLR7, human TLR8, mouse TLR8, human TLR9, and green puffer TLR, respectively, were used for the cross-dot matrices. The abscissa axis and the ordinate axis are residues number.

hTLR7	LRR1-LRR3	HVIVDCTDKHLTEIPGGIPTN	TTNLTLTINHIPDISPASFHRLDH	IVEIDFRNCV	PIPLGSKNNMCIKRLQIKPRSFSGLTY
	LRR4-LRR6	LKSLYLDGNQLLEIPQGLPSS	LQLLSLEANNIFSIKRNLTLAN	IEILYLGQNCY	RNPCYVYSYIEKDAFLNLTK
	LRR7-LRR9	LKVLSLKDNNVTAVPTVLPST	LTELYLYNNMIAKIQEDDFNNLNQ	LQILDLSGNCV	RCYNAPFPCAPCKNNSPLQIPVNAFDALTE
mTLR7	LRR1-LRR3	HVIVDCTDKHLTEIPEGIPTN	TTNLTLTINHIPDISPASFHRLDH	LEEIDLRCNCV	PVLLGSKANVCTKRLQIRPGSFSGLS
	LRR4-LRR6	LKALYLDGNQLLEIPQGLPSS	LHLLSLEANNIFSIKRNLTLAN	IETLYLGQNCY	YRNPNCVYSYIEKDAFLVLRN
	LRR7-LRR9	LKVLSLKDNNVTAVPTTLPN	LLELYLYNNIHKIQENDFNNLNE	LQVLDLSGNCV	RCYNVPYPCPCENNSPLQIHDNAFNSLTE
hTLR8	LRR1-LRR3	SVIAECSNRRLQEVPTVIGKY	VTLEDLSDNFITHTINESFQGLQN	LTKINLNHNPN	VQHONGNPGIQSNGLNITDGAFLNLKN
	LRR4-LRR6	LRELLLEDNQLPQIPSGLPES	LTELSLIQNNIYNTKEGISRLIN	LKNLYLAWNCY	FNKVCEKTNIEDGVFETLTN
	LRR7-LRR9	LELLSLSFNSLSHVPPKLPSS	LRKLFLSNTQIKYISEEDFKGLIN	LTLLDLSGNCV	RCFNAPFPCVPCDGGASINIDRFQNLTLQ
mTLR8	LRR1-LRR3	LVIAECNHRQLHEVPTIGKY	VTNIDLSDNAITHITKESFQGLQN	LTKIDLHNNAK	QQHPNENKNGMNI TEGALLSLRN
	LRR4-LRR6	LTVLLEDNQLYTIIPAGLPES	LKELSLIQNNIFQVTKNNTFGLRN	LERLYLGWNCY	FKCNQTFKVEDGAFKNLIH
	LRR7-LRR9	LKVLSLSDNNLFYVPPKLPSS	LRKLFLSNAKIMNITQEDFKGLEN	LTLLDLSGNCV	RCYNAPFPCTPCENSSIIHPLAFQSLTLQ
hTLR9	LRR2-LRR3		VTLSLSLSSNRHHLHSDFAHLPS	LRHLNLKWNCP	PVGLSPMHFPCHMTIEPSTFLAVPT
	LRR4-LRR6	LEELNLSYNNIMTVPA LPKS	LISLSLSHTNIMLMDASLAGLHA	LRFLFMDGNCY	YKNPCRQALEVAPGALLGLGN
	LRR7-LRR9	LTHLSLKYNNLTVVPRNLPS	LEYLLSYNNRIKVLAPEDLANLTA	LRVLDVGGNCR	RC DHAPNPMCPCPRHFPQLHPDTFSHLSR
mTLR9	LRR2-LRR3		ITRSLISNRHHLHSDFAHLPS	LRQLNLKWNCP	PTGLSPLHFSCHMTIEPSTFLAMRT
	LRR4-LRR6	LEELNLSYNGITTVPR LPSS	LVNLSLSHTNIMLMDASLAGLYS	LRVLFMDGNCY	YKNPCTGAVKVTGPALLGLGN
	LRR7-LRR9	LTHLSLKYNNLTKVPRQLPSS	LEYLLSYNNLIVKLGPELANLTS	LRVLDVGGNCR	RC DHAPNPCIIECGQKSLHHPETFHHLSH
gpTLR	LRR2-LRR3	VVNVDCTERSLTDVPHGIPRD	VSNLTLTINHIPNFNSTSFQGLDN	LREVDMRCNCV	PVKIGPKDHICTKSVTIEENTFNSLKN
	LRR4-LRR6	LQSLYLDGNQLYSIPKGLPSS	LILLSLEVNHIYISKANLSEIRN	VEILYLGQNCY	YRNPNCFSYGIEDGAFLELYN
	LRR7-LRR9	LKLLSLKSNLSEIPHHLPSS	LKELYLYNNNFQSVSAEDFKNLTN	LEILDLSGNCV	RCYNVPFPCNCPNNAFLKISKEAFKTLTK
Consensus		LxxLxLxxNxLxxIPxxLPxx	LxxLxLxxNxLxxLxxxxFxxLxx	LxxLxLxxNCx	xxxxxxxxxxxxxxxxxxxxxxxxIxxxxFxxLxx
LRR Type		< S >	< T >	< T >	

**Figure 12**

Sequence alignment of super-repeat of LRRs within TLR7, TLR and TLR9 from human and mouse and TLR from green puffer. human TLR7 [Q9NYK1]; mouse TLR7 [P58682]; human TLR8 [Q9NR97]; mouse TLR8 [P58682]; human TLR9 [Q9NR96]; mouse TLR9 [Q9EQU3]; green puffer TLR [Q450D3]. Abbreviations: h, human; m, mouse; gp, green puffer.

asporin. Class II has three subclasses: lumican plus fibromodulin (IIA), PRELP plus keratocan (IIB), and osteoadherin (IIC). Class III consists of epiphycan, osteoglycin and opticin. Class IV is more distantly related and consists of chondroadherin and nyctalopin. Class V consists of podocan. Their classes except for class IV contain the super-motif. Super-motifs, S and T, similar to those in SLRP are also present in asporin-like proteins from human and mouse, mouse fibromodulin-like proteins, biglycan-like proteins from sea lamprey, oligodendrocyte-myelin and glycoprotein (OMGP), the FLRT family from human, mouse and Xenopus, and human ECM2 [8,62]. Furthermore, a preliminary analysis indicates that nephrocyan, a novel member of the SLRP family [63], contains an STT motif. These observations suggest strongly that "bacterial" and "typical" LRRs evolved from a common precursor.

**LRR variants in TLRs associated with diseases**

A number of amino acid polymorphisms, which occur in LRRs, have been reported in TLRs. Arbour *et al.*, [64] first identified two mutations of human TLR4, D299G and T399I, which were associated with diminished airway responsiveness to inhaled LPS. Since then, these two mutations have been studied for their association with

various infectious and inflammatory diseases; results regarding the effects of these mutations have been inconclusive [65-71]. D299G and T399I occur in LRR11 and LRR15, respectively (Figure 7). D299G is near the convex part, while T399I is located on the loop C-terminal to the convex part. Very recently, Ohara *et al.*, [72] reported that one mutation, T135A, was associated with poorly-differentiated gastric adenocarcinomas. T135A in LRR5 occur at position 9 in the HCS part (Figure 7). Such a mutation has been observed in many LRR proteins such as nyctalopin, keratocan, GPIb $\alpha$ , GPIb $\beta$  and GPIX, which are associated with human diseases [58]. Position 9 is generally occupied by Asn or Cy and sometimes by Thr or Ser, whose side chains form hydrogen bonds in the loop structure [58]. The T135A mutation may disrupt the hydrogen bond pattern in the loop.

Mouse TLR9 plays a role in defense against systemic mouse cytomegalovirus infection. Mice with the mutation, L499P, are highly susceptible to mouse cytomegalovirus infection and shows low levels of cytokine induction and natural killer activation on viral infection [73]. L499P is located at the short loop that connects the helical structure on the convex part (in LRR17) and the  $\beta$ -strand on concave part (in LRR18) (Figure 10). That is, L499P in



LRR18 occur at position 1 in the HCS part. The side chain of L499 is completely buried in the LRR arc. Such a mutation is also observed in *trk-A* and *nyctalopin*, which are associated with human diseases [58]. The mutation of D543A in human TLR8 abolishes the binding of CpG DNA [61]. D543A in LRR19 occur at position 1 in the VS part. Thus, D543A is located at the edge between the convex and the concave parts of the LRR arc. The Cys-to-Ala mutations in the VS part of LRR9 (C257A, C260A, C267A, and C270A) completely abolish signaling by TLR8 [61].

Hidaka *et al.*, [74] detected one mutation, F303, in human TLR3 in one of three patients with influenza-associated encephalopathy. This was a loss-of-function mutation. F303S in LRR12 is located at position 4 in the HCS part. The side chain of F303 is completely buried in the LRR arc. Two mutations, H539E and N541A, resulted in the loss of TLR3 activation and ligand binding functions [75]. These two mutations occur in LRR21.

## Conclusion

The new method of alignment proposed here rationalizes the difference in the repeat numbers of LRRs and their "phasing" within TLRs in different databases and for various species and isoforms. Moreover, the new method indicates that each of the six TLR families is characterized by their LRR motifs, their repeat numbers, and the motifs of cysteine clusters. The repeat number of LRRs is larger than those previously reported in databases. The central part in the LRR domains within the *TLR1* family and TLR4 has more irregular motifs compared with the N- and C-terminal parts. Moreover, the *TLR7* family contains a region with 58–73 residues in the central part of the LRR domain. The central parts are inferred to play a key role in the structure and/or function of their TLRs. The LRRs in TLRs form one or two horseshoe domains. The LRR arc of TLRs is also predicted to be nearly flat. Furthermore, the LRR supermotif in the *TLR7* family suggests strongly that "bacterial" and "typical" LRRs evolved from a common precursor. The present analysis should stimulate and facilitate various experimental studies to understand the molecular mechanism of TLR-ligand interactions.

## Methods

### Known structures of LRR proteins

The structures of twenty-two different LRR proteins have been determined. They are ribonuclease inhibitor (RI) [2NBH, I1DJ, LA4Y, 1Z7X], GTPase-activating protein (RanGAP) [1YRG, 1K5D, 1K5G], tropomodulin (Tmod) [1I00, 1PGV], S-phase kinase-associated protein 2 (Skp2) [1FQV], YopM [1G9U], four internalins, Inl-B [1D0B], Inl-H [1H6U], Inl-A [106T, 106V, 106S] and Inl-C [1XEU], spliceosomal U2A' protein [1A9N], mRNA export factor (TAP) [1FT8, 1F01], rab geranylgeranyltransferase  $\alpha$ -subunit (RabGGT $\alpha$ ) [1DCE, 1LTX], *Chlamydomonas*

outer arm dynein light chain 1 (DLC-1) [1DS9], polygalacturonase-inhibiting protein (PGIP) [10GQ], nogo receptor/nogo-66 receptor (NgR) [10ZN, 1P9A], glycoprotein Iba (GPIb $\alpha$ ) [1M0Z, 1GWB, 1QYY, 1M10, 1SQ0, 1P8V, 100K, 1P9A, 1U0N], decorin [1XCD, 1XKU, 1XEC], biglycan [2FT3], Slit [1W8A], CD14 [1WWL], follicle-stimulating hormone receptor (FSHR) [1XWD], TLR3 [1ZIW, 2A0Z], and human lingo-1 [2ID5].

### Amino acid sequences

The LRRs alignments within the TLR family were made for TLR1 from four species (human [Q15399, Q5FWG5, Q6FI64, Q32MK3], mouse [Q9EPQ1], pig [Q4LDR7, Q59HI9], Takifugu rubripes [Q5H727]); TLR2 from 17 species (human [O60603], mouse [Q9QUN7, Q8K3D9, Q811T5], pig [Q59HI8, Q5DX20, Q76L24], chicken [Q9DD78 (TLR2.1), Q9DGB6 (TLR2.2)], bovine [Q95LA9], rat [Q6YGU2], dog [Q689D1], rabbit [AAM50059], goat [ABI31733], horse [AAR08196], hamster [Q9R1F8], *Cynomolgus* monkey [Q95M53], domestic water buffalo [Q2PZH4], Nilgai [Q2V897], Takifugu rubripes [Q5H725], zebrafish [Q6TS42], Japanese flounder [Q76CT8]); TLR3 from 9 species (human [O15455, Q4VAL2, Q504W0], mouse [Q99MB1, Q3TM31, Q499F3], bovine [Q5TJ58, Q5TJ59], rat [Q7TNI8], buffalo [Q1G1A3], Rhesus macaque [Q3BBY1], Takifugu rubripes [Q5H721], zebrafish [Q6IWL5, Q32PW5], Japanese flounder [Q76CT7, Q76CT9]; TLR4 from 17 species (human [O00206, Q5VZ17, Q5VZ18, Q5VZ19], mouse [Q9QUK6, Q5RGT4, Q8K2T5], pig [Q68Y56, Q2TNK4, Q5F4K7, Q401C7], bovine [Q9GL65, Q6WCD5, Q8SQ55], rat [Q9QX05], hamster [Q9WV82], cat [P58727], lowland gorilla [Q8SPE8], horse [Q9MYW3], Pygmy chimpanzee [Q9TTN0], olive baboon [Q9TSP2], orangutan [Q8SPE9], Nilgai [Q2V898], American bison [Q3ZD70], dog [Q8SQH3], rabbit [AAM50060]; zebrafish [Q6NV08, Q6TS41 (TLR4b)]; TLR5 from 8 species (human [O60602], pig [Q59HI7], mouse [Q9JLF7], bovine [Q2LDA0], chicken [Q4ZJ82], Japanese house mouse [Q1ZZX0], Takifugu rubripes [Q5H720, Q5H716 (TLRS5)], rainbow trout [Q7ZT81]); TLR6 from 5 species (human [Q9Y2C9], mouse [Q9EPW9, Q7TPC5], rat [Q6P690], pig [Q59HI6, Q76L23], bovine [Q704V6, Q706D2]; TLR7 from 4 species (human [Q9NYK1], mouse [P58681, Q548J0], dog [Q2L4T3], Takifugu rubripes [Q5H719]); TLR8 from 4 species ((human [Q9NR97, Q495P4, Q495P6, Q495P7], mouse [P58682], pig [Q865R7], Takifugu rubripes [Q5H718]); TLR9 from 12 species (human [Q9NR96], mouse [Q9EQU3], pig [Q5I2M3, Q865R8], bovine [Q5I2M5, Q866B2], dog [Q5I2M8], cat [Q5I2M7], Japanese flounder [Q2ABQ3], horse [Q2EEY0], sheep Q5I2M4], Ma's night monkey [Q56R09], Gilthead sea bream [Q3L273, Q3L274], Takifugu rubripes [Q5H717]); TLR10 from two species (human [Q9BXR5, Q5FWG4, Q32MI7, Q32MI8],

pig [Q4LDR6, Q59HI5]); TLR11 from mouse [Q6R5P0, Q32ME8]; TLR12 from mouse [Q6QNU9]; TLR13 from mouse [Q6R5N8]; TLR14 from Takifugu rubripes [Q5H726] and zebrafish [XP\_687315]; TLR15 from chicken [ABB71177], TLR21 from Takifugu rubripes [NP\_001027751], TLR22 from Takifugu rubripes [Q5H723], TLR23 from Takifugu rubripes [AAW70378], and TLR from rainbow trout [Q6KCC7, Q4LBC9], Atlantic salmon [Q2A132], goldfish [Q801F9]), Japanese lamprey [Q33E92, Q33E93] and green puffer (Fragment [Q4S0D3]).

#### **The prediction of secondary structure, signal peptide and membrane-spanning region in protein**

The protein secondary structure prediction by SSpro4.0 [13,76,77] and Proteus [12,78] were utilized for the determination and assignments of LRRs within TLRs. Signal peptide prediction was performed by SignalP 3.0 [79,80]. The prediction of membrane-spanning regions in proteins was performed by the TMHMM Program [81,82]. The PFAM program [83] was used to detect LRRs in TLRs.

#### **Multiple sequence alignment, sequence similarity search and dot plot analysis**

Multiple sequence alignments and sequence similarity searches were performed at Bioinformatic Center, Institute for Chemical Research, Kyoto University [84]. Dot-matrix comparisons were performed using the Blossum90 scoring matrix. The program was made in house. Window sizes and stringencies are indicated in figure legends.

#### **Abbreviations**

Toll-like receptor: FTLR. Toll IL-receptor: FTIR. LPS: Lipopolysaccharide. LRR: ECD: Ectodomain. Leucine rich repeat. HCS: Highly conserved segment of LRR. VS: Variable segment of LRR. SLRP: Small leucine-rich repeat proteoglycans: FSHr, Follicle-stimulating hormone receptor.

#### **Authors' contributions**

NM (corresponding author) carried out the molecular genetic studies and wrote the manuscript. TT performed the dot plot analysis and contributed to the data analysis. EP performed the geometrical analysis of the known structure of TLR3. TM and MT participated in the sequence alignment. KY and YK conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.

#### **Acknowledgements**

We thank Dr. Robert H. Kretsinger of University of Virginia for his valuable suggestion and comments. This work was supported in part Grant-in-Aid for Scientific Research from the Ministry Education, Science, Sports, and Culture of Japan (16310135) (to N. M.).

#### **References**

1. Kaisho T, Akira S: **Toll-like receptor function and signaling.** *J Allergy Clin Immunol* 2006, **117(5)**:979-987.
2. Galiana-Arnoux D, Imler JL: **Toll-like receptors and innate antiviral immunity.** *Tissue Antigens* 2006, **67(4)**:T267-276.
3. Kumar A, Yu FS: **Toll-like receptors and corneal innate immunity.** *Curr Mol Med* 2006, **6(3)**:327-337.
4. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A: **The evolution of vertebrate Toll-like receptors.** *Proc Natl Acad Sci USA* 2005, **102(27)**:9577-9582.
5. Kobe B, Deisenhofer J: **The leucine-rich repeat: a versatile binding part.** *Trends Biochem Sci* 1994, **19(10)**:415-421.
6. Kobe B, Deisenhofer J: **Proteins with leucine-rich repeats.** *Curr Opin Struct Biol* 1995, **5(3)**:409-416.
7. Kobe B, Kajava AV: **The leucine-rich repeat as a protein recognition part.** *Curr Opin Struct Biol* 2001, **11(6)**:725-732.
8. Matsushima N, Enkhbayar P, Kamiya M, Osaki M, Kretsinger RH: **Leucine-rich repeats (LRRs): structure, function, evolution and interaction with ligands.** *Drug Design Reviews* 2005, **2(4)**:305-322.
9. Kajava AV: **Structural diversity of leucine-rich repeat proteins.** *J Mol Biol* 1998, **277(3)**:519-527.
10. Ohyanagi T, Matsushima N: **Classification of tandem leucine-rich repeats within a great variety of proteins.** *FASEB J* 1997, **11**:A949.
11. Matsushima N, Ohyanagi T, Tanaka T, Kretsinger RH: **Super-motifs and evolution of tandem leucine-rich repeats within the small proteoglycans - biglycan, decorin, lumican, fibromodulin, PRELP, keratocan, osteoadherin, epiphygan, and osteoglycin.** *Proteins* 2000, **38(2)**:210-225.
12. Kobe B, Deisenhofer J: **A structural basis of the interactions between leucine-rich repeats and protein ligands.** *Nature* 1995, **374(6518)**:183-186.
13. Kobe B, Deisenhofer J: **Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with ribonuclease A.** *J Mol Biol* 1996, **264(5)**:1028-1043.
14. Papageorgiou AC, Shapiro R, Acharya KR: **Molecular recognition of human angiogenin by placental ribonuclease inhibitor-an X-ray crystallographic study at 2.0 Å resolution.** *EMBO J* 1997, **16(17)**:5162-5177.
15. Hillig RC, Renault L, Vetter IR, Drell T 4th, Wittinghofer A, Becker J: **The crystal structure of rnalp: a new fold for a GTPase-activating protein.** *Mol Cell* 1999, **3(6)**:781-791.
16. Seewald MJ, Korner C, Wittinghofer A, Vetter IR: **RanGAP mediates GTP hydrolysis without an arginine finger.** *Nature* 2002, **415(6872)**:662-666.
17. Krieger I, Kostyukova A, Yamashita A, Nitani Y, Maeda Y: **Crystal structure of the C-terminal half of tropomodulin and structural basis of actin filament pointed-end capping.** *Biophys J* 2002, **83(5)**:2716-2725.
18. Lu S, Symersky J, Li S, Carson M, Chen L, Meehan E, Luo M: **Structural genomics of Caenorhabditis elegans: crystal structure of the tropomodulin C-terminal domain.** *Proteins* 2004, **56(2)**:384-386.
19. Schulman BA, Carrano AC, Jeffrey PD, Bowen Z, Kinnucan ER, Finnin MS, Elledge SJ, Harper JW, Pagano M, Pavletich NP: **Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex.** *Nature* 2000, **408(6810)**:381-386.
20. Hao B, Zheng N, Schulman BA, Wu G, Miller JJ, Pagano M, Pavletich NP: **Structural basis of the Cks1-dependent recognition of p27(Kip1) by the SCF(Skp2) ubiquitin ligase.** *Mol Cell* 2005, **20(1)**:9-19.
21. Evdokimov AG, Anderson DE, Rutzahn KM, Waugh DS: **Unusual molecular architecture of the Yersinia pestis cytotoxin YopM: a leucine-rich repeat protein with the shortest repeating unit.** *J Mol Biol* 2001, **312(4)**:807-821.
22. Marino M, Braun L, Cossart P, Ghosh P: **Structure of the InlB leucine-rich repeats, a domain that triggers host cell invasion by the bacterial pathogen L. monocytogenes.** *Mol Cell* 1999, **4(6)**:1063-1072.
23. Schubert WD, Gobel G, Diepholz M, Darji A, Kloer D, Hain T, Chakraborty T, Wehland J, Domann E, Heinz DW: **Internalins from the human pathogen Listeria monocytogenes combine three distinct folds into a contiguous internalin domain.** *J Mol Biol* 2001, **312(4)**:783-794.
24. Marino M, Banerjee M, Jonquieres R, Cossart P, Ghosh P: **GW domains of the Listeria monocytogenes invasion protein InlB are SH3-like and mediate binding to host ligands.** *EMBO J* 2002, **21(21)**:5623-5634.
25. Marino M, Banerjee M, Copp J, Dramsi S, Chapman T, van der Geer P, Cossart P, Ghosh P: **Characterization of the calcium-binding**

- sites of *Listeria monocytogenes* InlB. *Biochem Biophys Res Commun* 2004, **316**(2):379-386.
26. Schubert WD, Urbanke C, Ziehm T, Beier V, Machner MP, Domann E, Wehland J, Chakraborty T, Heinz DW: **Structure of internalin, a major invasion protein of *Listeria monocytogenes*, in complex with its human receptor E-cadherin.** *Cell* 2002, **111**(6):825-836.
  27. Price SR, Evans PR, Nagai K: **Crystal structure of the spliceosomal U2B"-U2A' protein complex bound to a fragment of U2 small nuclear RNA.** *Nature* 1998, **394**(6694):645-650.
  28. Liker E, Fernandez E, Izaurralde E, Conti E: **The structure of the mRNA export factor TAP reveals a cis arrangement of a non-canonical RNP domain and an LRR domain.** *EMBO J* 2000, **19**(21):5587-5598.
  29. Ho DN, Coburn GA, Kang Y, Cullen BR, Georgiadis MM: **The crystal structure and mutational analysis of a novel RNA-binding domain found in the human Tap nuclear mRNA export factor.** *Proc Natl Acad Sci USA* 2002, **99**(4):1888-1893.
  30. Zhang H, Seabra MC, Deisenhofer J: **Crystal structure of Rab geranylgeranyltransferase at 2.0 Å resolution.** *Structure* 2000, **8**(3):241-251.
  31. Pylipenko O, Rak A, Reents R, Niculae A, Sidorovitch V, Cioaca MD, Bessolitsyna E, Thoma NH, Waldmann H, Schlichting I, Goody RS, Alexandrov K: **Structure of Rab escort protein-1 in complex with Rab geranylgeranyltransferase.** *Mol Cell* 2003, **11**(2):483-494.
  32. Wu H, Maciejewski MW, Marintchev A, Benashski SE, Mullen GP, King SM: **Solution structure of a dynein motor domain associated light chain.** *Nat Struct Biol* 2000, **7**(7):575-579.
  33. Wu H, Blackledge M, Maciejewski MW, Mullen GP, King SM: **Relaxation-based structure refinement and backbone molecular dynamics of the dynein motor domain-associated light chain.** *Biochemistry* 2003, **42**(1):57-71.
  34. Di Matteo A, Federici L, Mattei B, Salvi G, Johnson KA, Savino C, De Lorenzo G, Tsernoglou D, Cervone F: **The crystal structure of polygalacturonase-inhibiting protein (PGIP), a leucine-rich repeat protein involved in plant defense.** *Proc Natl Acad Sci USA* 2003, **100**(17):10124-10128.
  35. Barton WA, Liu BP, Tzvetkova D, Jeffrey PD, Fournier AE, Sah D, Cate R, Strittmatter SM, Nikolov DB: **Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins.** *EMBO J* 2003, **22**(13):3291-302.
  36. He XL, Bazan JF, McDermott G, Park JB, Wang K, Tessier-Lavigne M, He Z, Garcia KC: **Structure of the Nogo receptor ectodomain: a recognition module implicated in myelin inhibition.** *Neuron* 2003, **38**(2):177-185.
  37. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, Gros P: **Structures of glycoprotein Ibalph and its complex with von Willebrand factor A1 domain.** *Science* 2002, **297**(5584):1176-1179.
  38. Uff S, Clemetson JM, Harrison T, Clemetson KJ, Emsley J: **Crystal structure of the platelet glycoprotein Ib(alpha) N-terminal domain reveals an unmasking mechanism for receptor activation.** *J Biol Chem* 2002, **277**(38):35657-35663.
  39. Dumas JJ, Kumar R, Seehra J, Somers WS, Mosyak L: **Crystal structure of the plbalpha-thrombin complex essential for platelet aggregation.** *Science* 2003, **301**(5630):222-226.
  40. Celikel R, McClintock RA, Roberts JR, Mendolicchio GL, Ware J, Varughese KI, Ruggeri ZM: **Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalph.** *Science* 2003, **301**(5630):218-221.
  41. Dumas JJ, Kumar R, McDonagh T, Sullivan F, Stahl ML, Somers WS, Mosyak L: **Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalph complex reveals conformational differences with a complex bearing von Willebrand disease mutations.** *J Biol Chem* 2004, **279**(22):23327-23334.
  42. Varughese KI, Ruggeri ZM, Celikel R: **Platinum-induced space-group transformation in crystals of the platelet glycoprotein Ib alpha N-terminal domain.** *Acta Crystallogr D Biol Crystallogr* 2004, **60**(3):405-411.
  43. Fukuda K, Doggett T, Laurenzi IJ, Liddington RC, Diacovo TG: **The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation.** *Nat Struct Mol Biol* 2005, **2**(2):152-159.
  44. Scott PG, McEwan PA, Dodd CM, Bergmann EM, Bishop PN, Bella J: **Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan.** *Proc Natl Acad Sci USA* 2004, **101**(44):15633-15638.
  45. Scott PG, Dodd CM, Bergmann EM, Sheehan JK, Bishop PN: **Crystal structure of the biglycan dimer and evidence that dimerization is essential for folding and stability of class I small leucine-rich repeat proteoglycans.** *J Biol Chem* 2006, **281**(19):13324-13332.
  46. Howitt JA, Clout NJ, Hohenester E: **Binding site for Robo receptors revealed by dissection of the leucine-rich repeat region of Slit.** *EMBO J* 2004, **23**(22):4406-4412.
  47. Fan QR, Hendrickson WA: **Structure of human follicle-stimulating hormone in complex with its receptor.** *Nature* 2005, **433**(7023):269-277.
  48. Kim JJ, Lee CJ, Jin MS, Lee CH, Paik SG, Lee H, Lee JO: **Crystal structure of CD14 and its implications for lipopolysaccharide signaling.** *J Biol Chem* 2005, **280**(12):11347-11351.
  49. Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR: **The molecular structure of the Toll-like receptor 3 ligand-binding domain.** *Proc Natl Acad Sci USA* 2005, **102**(31):10976-10980.
  50. Choe J, Kelker MS, Wilson IA: **Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.** *Science* 2005, **309**(5734):581-585.
  51. Mosyak L, Wood A, Dwyer B, Buddha M, Johnson M, Aulabaugh A, Zhong X, Presman E, Benard S, Kelleher K, Wilhelm J, Stahl ML, Kriz R, Gao Y, Cao Z, Ling HP, Pangalos MN, Walsh FS, Somers WS: **The structure of the Lingo-1 ectodomain, a module implicated in CNS repair inhibition.** *J Biol Chem* 2006, **281**(47):36378-36390.
  52. Montgomerie S, Sundararaj S, Gallin WJ, Wishart DS: **Improving the accuracy of protein secondary structure prediction using structural alignment.** *BMC Bioinformatics* 2006, **7**:301-313.
  53. Pollastri G, McLysaght A: **Porter: a new, accurate server for protein secondary structure prediction.** *Bioinformatics* 2005, **21**(8):1719-1720.
  54. Kneller DG, Cohen FE, Langridge R: **Improvements in Protein Secondary Structure Prediction by an Enhanced Neural Network.** *J Mol Biol* 1990, **214**:171-182.
  55. Enkhbayar P, Kamiya M, Osaki M, Matsumoto T, Matsushima N: **Structural principles of leucine-rich repeat (LRR) proteins.** *Proteins* 2004, **54**(3):394-403.
  56. Asahina Y, Yoshioka N, Kano R, Moritomo T, Hasegawa A: **Full-length cDNA cloning of Toll-like receptor 4 in dogs and cats.** *Vet Immunol Immunopathol* 2003, **96**(3-4):159-167.
  57. Hirono I, Takami M, Miyata M, Miyazaki T, Han HJ, Takano T, Endo M, Aoki T: **Characterization of gene structure and expression of two toll-like receptors from Japanese flounder, *Paralichthys olivaceus*.** *Immunogenetics* 2004, **56**(1):38-46.
  58. Matsushima N, Tachi N, Kuroki Y, Enkhbayar P, Osaki M, Kamiya M, Kretsinger RH: **Structural analysis of leucine-rich-repeat variants in proteins associated with human diseases.** *Cell Mol Life Sci* 2005, **62**(23):2771-2791.
  59. Nishitani C, Mitsuzawa H, Sano H, Shimizu T, Matsushima N, Kuroki Y: **Toll-like receptor 4 region Glu<sup>24</sup>-Lys<sup>47</sup> is a site for MD-2 binding: Importance of Cys<sup>29</sup> and Cys<sup>40</sup>.** *J Biol Chem* 2006, **281**(50):38322-38329.
  60. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM: **Leucine-rich repeats and pathogen recognition in Toll-like receptors.** *Trends Immunol* 2003, **24**(10):528-533.
  61. Gibbard RJ, Morley PJ, Gay NJ: **Conserved features in the extracellular domain of human toll-like receptor 8 are essential for pH dependent signaling.** *J Biol Chem* 2006, **281**(37):27503-27511.
  62. McEwan PA, Scott PG, Bishop PN, Bella J: **Structural correlations in the family of small Leucine-rich repeat proteins and proteoglycans.** *J Struct Biol* 2006, **155**(2):294-305.
  63. Mochida Y, Parisuthiman D, Kaku M, Hanai JI, Sukhatme VP, Yamauchi M: **Nephrocan, a novel member of the small leucine-rich repeat protein family, is an inhibitor of transforming growth factor-beta signaling.** *J Biol Chem* 2006 in press.
  64. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA: **TLR4 mutations are associated with endotoxin hyporesponsiveness in humans.** *Nat Genet* 2000, **25**:187-191.
  65. Vogel SN, Awomoyi AA, Rallabhandi P, Medvedev AE: **Mutations in TLR4 signaling that lead to increased susceptibility to infection in humans: an overview.** *J Endotoxin Res* 2005, **11**(6):333-339.
  66. Kang SS, Kauls LS, Gaspari AA: **Toll-like receptors: applications to dermatologic disease.** *J Am Acad Dermatol* 2006, **54**(6):951-983.
  67. Pandey S, Agrawal DK: **Immunobiology of Toll-like receptors: Emerging trends.** *Immunol Cell Biol* 2006, **84**(4):333-341.
  68. Kumpf O, Hamann L, Schlag PM, Schumann RR: **Pre- and postoperative cytokine release after in vitro whole blood lipopolysaccharide stimulation and frequent toll-like receptor 4 polymorphisms.** *Shock* 2006, **25**(2):123-128.
  69. Faber J, Meyer CU, Gemmer C, Russo A, Finn A, Murdoch C, Zenz W, Mannhalter C, Zabel BU, Schmitt HJ, Habermehl P, Zepp F, Knuf M: **Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy.** *Pediatr Infect Dis J* 2006, **25**(1):80-81.

70. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR, Otchwemah RN, Dietz E, Ehrhardt S, Schroder NW, Bienzle U, Schumann RR: **Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria.** *Proc Natl Acad Sci USA* 2006, **103(1)**:177-182.
71. Montes AH, Asensi V, Alvarez V, Valle E, Ocana MG, Meana A, Carton JA, Paz J, Fierer J, Celada A: **The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis.** *Clin Exp Immuno* 2006, **143(3)**:404-413.
72. Ohara T, Morishita T, Suzuki H, Hibi T: **Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas.** *Int J Mol Med* 2006, **18(1)**:59-63.
73. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel L, Sovath S, Goode J, Alexopoulou L, Flavell RA, Beutler B: **Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection.** *Proc Natl Acad Sci USA* 2004, **101(10)**:3516-3521.
74. Hidaka F, Matsuo S, Muta T, Takeshige K, Mizukami T, Nunoi H: **A missense mutation of the Toll-like receptor 3 gene in a patient with influenza-associated encephalopathy.** *Clin Immunol* 2006, **119(2)**:188-194.
75. Bell JK, Askins J, Hall PR, Davies DR, Segal DM: **The dsRNA binding site of human Toll-like receptor 3.** *Proc Natl Acad Sci USA* 2006, **103(23)**:8792-8797.
76. Cheng J, Randall AZ, Sweredoski MJ, Baldi P: **SCRATCH: a protein structure and structural feature prediction server.** *Nucleic Acids Res* 2005, **33**:W72-76.
77. [<http://contact.ics.uci.edu/sspro4.html>].
78. [<http://129.128.185.184/proteus/#>].
79. Bendtsen JD, Nielsen H, von Heijne G, Brunak S: **Improved prediction of signal peptides: SignalP 3.0.** *J Mol Biol* 2004, **340(4)**:783-795.
80. [<http://www.cbs.dtu.dk/services/SignalP/>].
81. Moller S, Croning MD, Apweiler R: **Evaluation of methods for the prediction of membrane spanning regions.** *Bioinformatics* 2001, **17(7)**:646-653.
82. [<http://www.cbs.dtu.dk/services/TMHMM/>].
83. [<http://pfam.janelia.org/>].
84. [<http://www.genome.ad.jp/>].

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

